Jan H.M. Schellens - Publications

Affiliations: 
Utrecht University, Utrecht, Netherlands 
Area:
pharmaceutical toxicology
Website:
http://profs.library.uu.nl/index.php/profrec/getprofdata/1828/56/79/0

500 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2021 Geenen JJ, Dackus GM, Schouten PC, Pluim D, Marchetti S, Sonke GS, Jóźwiak K, Huitema AD, Beijnen JH, Schellens JH, Linn SC. A phase I dose-escalation study of two cycles carboplatin-olaparib followed by olaparib monotherapy in patients with advanced cancer. International Journal of Cancer. PMID 33539540 DOI: 10.1200/Jco.2019.37.15_Suppl.3118  0.47
2020 van Brummelen EMJ, Huijberts S, van Herpen C, Desar I, Opdam F, van Geel R, Marchetti S, Steeghs N, Monkhorst K, Thijssen B, Rosing H, Huitema A, Beijnen J, Bernards R, Schellens J. Phase I Study of Afatinib and Selumetinib in Patients with KRAS-Mutated Colorectal, Non-Small Cell Lung, and Pancreatic Cancer. The Oncologist. 26: 290-e545. PMID 33296125 DOI: 10.1002/onco.13631  0.363
2020 Huijberts S, Wang L, de Oliveira RL, Rosing H, Nuijen B, Beijnen J, Bernards R, Schellens J, Wilgenhof S. Vorinostat in patients with resistant mutated advanced melanoma: a proof of concept study. Future Oncology (London, England). PMID 32125175 DOI: 10.2217/Fon-2020-0023  0.394
2018 van Andel L, Rosing H, Schellens JH, Beijnen JH. Review of Chromatographic Bioanalytical Assays for the Quantitative Determination of Marine-Derived Drugs for Cancer Treatment. Marine Drugs. 16. PMID 30041477 DOI: 10.3390/Md16070246  0.383
2018 Rodon J, Pérez-Fidalgo A, Krop IE, Burris H, Guerrero-Zotano A, Britten CD, Becerra C, Schellens J, Richards DA, Schuler M, Abu-Khalaf M, Johnson FM, Ranson M, Edenfield J, Silva AP, et al. Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer. Cancer Chemotherapy and Pharmacology. PMID 29882016 DOI: 10.1007/S00280-018-3610-Z  0.358
2017 Henricks LM, Siemerink EJ, Rosing H, Meijer J, Goorden SM, Polstra AM, Zoetekouw L, Cats A, Schellens JH, van Kuilenburg AB. Capecitabine-based treatment of a patient with a novel DPYD genotype and complete dihydropyrimidine dehydrogenase deficiency. International Journal of Cancer. PMID 28929491 DOI: 10.1002/Ijc.31065  0.396
2017 van Geel RM, Tabernero J, Elez E, Bendell JC, Spreafico A, Schuler M, Yoshino T, Delord JP, Yamada Y, Lolkema M, Faris JE, Eskens FA, Sharma S, Yaeger R, Lenz HJ, ... ... Schellens JH, et al. A Phase 1b Dose-Escalation Study of Encorafenib (LGX818) and Cetuximab With or Without Alpelisib in Metastatic BRAF-Mutant Colorectal Cancer. Cancer Discovery. PMID 28363909 DOI: 10.1158/2159-8290.Cd-16-0795  0.359
2017 de Jonge M, de Weger VA, Dickson MA, Langenberg M, Le Cesne A, Wagner AJ, Hsu K, Zheng W, Macé S, Tuffal G, Thomas K, Schellens JH. A phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumours. European Journal of Cancer (Oxford, England : 1990). 76: 144-151. PMID 28324749 DOI: 10.1016/J.Ejca.2017.02.005  0.343
2017 van Andel L, Zhang Z, Lu S, Kansra V, Agarwal S, Hughes L, Tibben MM, Gebretensae A, Lucas L, Hillebrand MJ, Rosing H, Schellens JH, Beijnen JH. Human mass balance study and metabolite profiling of (14)C-niraparib, a novel poly(ADP-Ribose) polymerase (PARP)-1 and PARP-2 inhibitor, in patients with advanced cancer. Investigational New Drugs. PMID 28303528 DOI: 10.1007/S10637-017-0451-2  0.519
2017 Verheijen RB, Beijnen JH, Schellens JH, Huitema AD, Steeghs N. Clinical Pharmacokinetics and Pharmacodynamics of Pazopanib: Towards Optimized Dosing. Clinical Pharmacokinetics. PMID 28185218 DOI: 10.1007/S40262-017-0510-Z  0.451
2017 Nijenhuis CM, Lucas L, Rosing H, Huitema AD, Mergui-Roelvink M, Jamieson GC, Fox JA, Mould DR, Schellens JH, Beijnen JH. Metabolism and disposition of the anticancer quinolone derivative vosaroxin, a novel inhibitor of topoisomerase II. Investigational New Drugs. PMID 28138829 DOI: 10.1007/S10637-017-0428-1  0.518
2017 van Andel L, Fudio S, Rosing H, Munt S, Miguel-Lillo B, González I, Tibben MM, de Vries N, de Vries Schultink AH, Schellens JH, Beijnen JH. Pharmacokinetics and excretion of (14)C-Plitidepsin in patients with advanced cancer. Investigational New Drugs. PMID 28111728 DOI: 10.1007/S10637-017-0432-5  0.498
2017 Sawicki E, Schellens JH, Beijnen JH, Nuijen B. Pharmaceutical development of an amorphous solid dispersion formulation of elacridar hydrochloride for proof-of-concept clinical studies. Drug Development and Industrial Pharmacy. 43: 584-594. PMID 28010129 DOI: 10.1080/03639045.2016.1274901  0.42
2017 Schellens JH, Marabelle A, Zeigenfuss S, Ding J, Pruitt SK, Chung HC. Pembrolizumab for previously treated advanced cervical squamous cell cancer: Preliminary results from the phase 2 KEYNOTE-158 study. Journal of Clinical Oncology. 35: 5514-5514. DOI: 10.1200/Jco.2017.35.15_Suppl.5514  0.334
2017 van Bussel M, Mau-Soerensen M, Damstrup L, Nielsen D, Verheul HM, Aftimos PG, De Jonge MJ, Berghoff K, Schellens JH. A multicenter phase I trial of the DNA-dependent protein kinase (DNA-PK) inhibitor M3814 in patients with solid tumors. Journal of Clinical Oncology. 35: 2556-2556. DOI: 10.1200/Jco.2017.35.15_Suppl.2556  0.34
2017 Verheijen RB, van Duijl TT, van den Heuvel MM, Beijnen JH, Schellens JH, van den Broek D, Steeghs N, Huitema A. Monitoring of circulating tumor DNA in non-small cell lung cancer patients treated with EGFR-inhibitors. Journal of Clinical Oncology. 35: 11535-11535. DOI: 10.1200/Jco.2017.35.15_Suppl.11535  0.433
2017 van Bussel M, Pluim D, Milojkovic-Kerklaan B, van den Broek D, Beijnen J, Boogerd W, Schellens J, Rhun EL, Brandsma D. CMET-12. TUMOR CELL DETECTION BY IMMUNOFLOW CYTOMETRY AND BRAF MUTATION ANALYSIS IN CEREBROSPINAL FLUID OF MELANOMA PATIENTS WITH SUSPECTED LEPTOMENINGEAL METASTASES Neuro-Oncology. 19: vi41-vi41. DOI: 10.1093/Neuonc/Nox168.161  0.395
2017 Herbrink M, Schellens J, Beijnen J, Nuijen B. Thermal study of pazopanib hydrochloride Journal of Thermal Analysis and Calorimetry. 130: 1491-1499. DOI: 10.1007/S10973-017-6286-4  0.404
2016 de Krou S, Rosing H, Nuijen B, Schellens JH, Beijnen JH. Fast and adequate liquid chromatography-tandem mass spectrometric determination of Z-endoxifen serum levels for therapeutic drug monitoring. Therapeutic Drug Monitoring. PMID 28045782 DOI: 10.1097/Ftd.0000000000000372  0.483
2016 Leijen S, van Geel RM, Sonke GS, de Jong D, Rosenberg EH, Marchetti S, Pluim D, van Werkhoven E, Rose S, Lee MA, Freshwater T, Beijnen JH, Schellens JH. Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 34: 4354-4361. PMID 27998224 DOI: 10.1200/Jco.2016.67.5942  0.462
2016 van Andel L, Zhang Z, Lu S, Kansra V, Agarwal S, Hughes L, Tibben MM, Gebretensae A, Rosing H, Schellens JH, Beijnen JH. Liquid chromatography-tandem mass spectrometry assay for the quantification of niraparib and its metabolite M1 in human plasma and urine. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 1040: 14-21. PMID 27898364 DOI: 10.1016/J.Jchromb.2016.11.020  0.497
2016 Nogova L, Sequist LV, Perez Garcia JM, Andre F, Delord JP, Hidalgo M, Schellens JH, Cassier PA, Camidge DR, Schuler M, Vaishampayan U, Burris H, Tian GG, Campone M, Wainberg ZA, et al. Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2016672048. PMID 27870574 DOI: 10.1200/Jco.2016.67.2048  0.372
2016 Sawicki E, Verheijen RB, Huitema AD, van Tellingen O, Schellens JH, Nuijen B, Beijnen JH, Steeghs N. Clinical pharmacokinetics of an amorphous solid dispersion tablet of elacridar. Drug Delivery and Translational Research. PMID 27864786 DOI: 10.1007/S13346-016-0346-3  0.49
2016 Sawicki E, Schellens JH, Beijnen JH, Nuijen B. Inventory of oral anticancer agents: Pharmaceutical formulation aspects with focus on the solid dispersion technique. Cancer Treatment Reviews. 50: 247-263. PMID 27776286 DOI: 10.1016/J.Ctrv.2016.09.012  0.461
2016 Herbrink M, de Vries N, Rosing H, Huitema AD, Nuijen B, Schellens JH, Beijnen JH. Quantification of 11 Therapeutic Kinase Inhibitors in Human Plasma for Therapeutic Drug Monitoring Using Liquid Chromatography Coupled With Tandem Mass Spectrometry. Therapeutic Drug Monitoring. 38: 649-656. PMID 27749781 DOI: 10.1097/Ftd.0000000000000349  0.473
2016 Sparidans RW, Rosing H, Rood JJ, Schellens JH, Beijnen JH. Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the B-Raf inhibitor encorafenib, the EGFR inhibitors afatinib, erlotinib and gefitinib and the O-desmethyl metabolites of erlotinib and gefitinib in human plasma. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 1033: 390-398. PMID 27639128 DOI: 10.1016/J.Jchromb.2016.09.012  0.457
2016 Leijen S, van Geel RM, Pavlick AC, Tibes R, Rosen L, Razak AR, Lam R, Demuth T, Rose S, Lee MA, Freshwater T, Shumway S, Liang LW, Oza AM, Schellens JH, et al. Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 27601554 DOI: 10.1200/Jco.2016.67.5991  0.321
2016 Meulendijks D, Cats A, Beijnen JH, Schellens JH. Improving safety of fluoropyrimidine chemotherapy by individualizing treatment based on dihydropyrimidine dehydrogenase activity - Ready for clinical practice? Cancer Treatment Reviews. 50: 23-34. PMID 27589829 DOI: 10.1016/J.Ctrv.2016.08.002  0.452
2016 Meulendijks D, Henricks LM, van Kuilenburg AB, Jacobs BA, Aliev A, Rozeman L, Meijer J, Beijnen JH, de Graaf H, Cats A, Schellens JH. Patients homozygous for DPYD c.1129-5923C>G/haplotype B3 have partial DPD deficiency and require a dose reduction when treated with fluoropyrimidines. Cancer Chemotherapy and Pharmacology. PMID 27544765 DOI: 10.1007/S00280-016-3137-0  0.389
2016 Yu H, van Erp N, Bins S, Mathijssen RH, Schellens JH, Beijnen JH, Steeghs N, Huitema AD. Development of a Pharmacokinetic Model to Describe the Complex Pharmacokinetics of Pazopanib in Cancer Patients. Clinical Pharmacokinetics. PMID 27534647 DOI: 10.1007/S40262-016-0443-Y  0.449
2016 Sawicki E, Beijnen JH, Schellens JH, Nuijen B. Pharmaceutical development of an oral tablet formulation containing a spray dried amorphous solid dispersion of docetaxel or paclitaxel. International Journal of Pharmaceutics. PMID 27480397 DOI: 10.1016/J.Ijpharm.2016.07.068  0.439
2016 Verheijen RB, Bins S, Mathijssen RH, Lolkema M, van Doorn L, Schellens JH, Beijnen JH, Langenberg MH, Huitema AD, Steeghs N. Individualized pazopanib dosing: a prospective feasibility study in cancer patients. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27470967 DOI: 10.1158/1078-0432.Ccr-16-1255  0.473
2016 Rood JJ, van Bussel MT, Schellens JH, Beijnen JH, Sparidans RW. Liquid chromatography-tandem mass spectrometric assay for the T790M mutant EGFR inhibitor osimertinib (AZD9291) in human plasma. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 1031: 80-85. PMID 27469903 DOI: 10.1016/J.Jchromb.2016.07.037  0.478
2016 Rood JJ, Schellens JH, Beijnen JH, Sparidans RW. Recent developments in the chromatographic bioanalysis of approved kinase inhibitor drugs in oncology. Journal of Pharmaceutical and Biomedical Analysis. PMID 27460293 DOI: 10.1016/J.Jpba.2016.06.037  0.465
2016 van Brummelen EM, Ros W, Wolbink G, Beijnen JH, Schellens JH. Antidrug Antibody Formation in Oncology: Clinical Relevance and Challenges. The Oncologist. PMID 27440064 DOI: 10.1634/Theoncologist.2016-0061  0.439
2016 Nijenhuis CM, Huitema AD, Blank C, Haanen JB, van Thienen JV, Rosing H, Schellens JH, Beijnen JH. Clinical Pharmacokinetics of Vemurafenib in BRAF-Mutated Melanoma Patients. Journal of Clinical Pharmacology. PMID 27365214 DOI: 10.1002/Jcph.788  0.462
2016 Schouten PC, Dackus GM, Marchetti S, van Tinteren H, Sonke GS, Schellens JH, Linn SC. A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trial. Trials. 17: 293. PMID 27323902 DOI: 10.1186/S13063-016-1423-0  0.309
2016 Oddo D, Sennott EM, Barault L, Valtorta E, Arena S, Cassingena A, Filiciotto G, Marzolla G, Elez E, van Geel RM, Bartolini A, Crisafulli G, Boscaro V, Godfrey JT, Buscarino M, ... ... Schellens JH, et al. Molecular landscape of acquired resistance to targeted therapy combinations in BRAF mutant colorectal cancer. Cancer Research. PMID 27312529 DOI: 10.1158/0008-5472.Can-16-0396  0.317
2016 Nijenhuis CM, Lucas L, Rosing H, Jamieson G, Fox JA, Schellens JH, Beijnen JH. Quantification of vosaroxin and its metabolites N-desmethylvosaroxin and O-desmethylvosaroxin in human plasma and urine using high-performance liquid chromatography-tandem mass spectrometry. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 1027: 1-10. PMID 27236532 DOI: 10.1016/J.Jchromb.2016.05.016  0.473
2016 Nijenhuis CM, Hellriegel E, Beijnen JH, Hershock D, Huitema AD, Lucas L, Mergui-Roelvink M, Munteanu M, Rabinovich-Guilatt L, Robertson P, Rosing H, Spiegelstein O, Schellens JH. Pharmacokinetics and excretion of (14)C-omacetaxine in patients with advanced solid tumors. Investigational New Drugs. PMID 27221729 DOI: 10.1007/S10637-016-0360-9  0.503
2016 Nijenhuis CM, Schellens JH, Beijnen JH. Regulatory aspects of human radiolabeled mass balance studies in oncology: concise review. Drug Metabolism Reviews. 48: 266-80. PMID 27186889 DOI: 10.1080/03602532.2016.1181081  0.427
2016 Sparidans RW, Kort A, Schinkel AH, Schellens JH, Beijnen JH. Liquid chromatography-tandem mass spectrometric assay for ponatinib and N-desmethyl ponatinib in mouse plasma. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 1023: 24-29. PMID 27179188 DOI: 10.1016/J.Jchromb.2016.04.049  0.482
2016 Jacobs BA, Rosing H, de Vries N, Meulendijks D, Henricks LM, Schellens JH, Beijnen JH. Development and validation of a rapid and sensitive UPLC-MS/MS method for determination of uracil and dihydrouracil in human plasma. Journal of Pharmaceutical and Biomedical Analysis. 126: 75-82. PMID 27179185 DOI: 10.1016/J.Jpba.2016.04.039  0.455
2016 Deenen MJ, Cats A, Severens JL, Beijnen JH, Schellens JH. Reply to T. Magnes et al. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 27161961 DOI: 10.1200/Jco.2016.67.4374  0.321
2016 Jacobs BA, Deenen MJ, Pluim D, van Hasselt JG, Krähenbühl MD, van Geel RM, de Vries N, Rosing H, Meulendijks D, Burylo AM, Cats A, Beijnen JH, Huitema AD, Schellens JH. Pronounced between-subject and circadian variability in thymidylate synthase and dihydropyrimidine dehydrogenase enzyme activity in human volunteers. British Journal of Clinical Pharmacology. PMID 27161955 DOI: 10.1111/Bcp.13007  0.661
2016 Jacobs BA, Meulenaar J, Rosing H, Pluim D, Tibben MM, de Vries N, Nuijen B, Huitema AD, Beijnen JH, Schellens JH, Marchetti S. A phase 0 clinical trial of novel candidate extended-release formulations of capecitabine. Cancer Chemotherapy and Pharmacology. PMID 27103124 DOI: 10.1007/S00280-016-3035-5  0.404
2016 Dubbelman AC, Tibben M, Rosing H, Gebretensae A, Nan L, Gorman SH, Robertson P, Schellens JH, Beijnen JH. Corrigendum to "Development and validation of LC-MS/MS assays for the quantification of bendamustine and its metabolites in human plasma and urine" [J. Chromatogr. B: Anal. Technol. Biomed. Life Sci. 893-894 (2012) 92-100]. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 1020: 168-169. PMID 27063483 DOI: 10.1016/J.Jchromb.2016.03.016  0.418
2016 Nijenhuis CM, Haverkate H, Rosing H, Schellens JH, Beijnen JH. Simultaneous quantification of dabrafenib and trametinib in human plasma using high-performance liquid chromatography-tandem mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis. 125: 270-9. PMID 27058232 DOI: 10.1016/J.Jpba.2016.03.049  0.495
2016 Milojkovic Kerklaan B, Slater S, Flynn M, Greystoke A, Witteveen PO, Megui-Roelvink M, de Vos F, Dean E, Reyderman L, Ottesen L, Ranson M, Lolkema MP, Plummer R, Kristeleit R, Evans TR, ... Schellens JH, et al. A phase I, dose escalation, pharmacodynamic, pharmacokinetic, and food-effect study of α2 integrin inhibitor E7820 in patients with advanced solid tumors. Investigational New Drugs. 34: 329-37. PMID 27039386 DOI: 10.1007/S10637-016-0344-9  0.342
2016 Dubbelman AC, Nijenhuis CM, Jansen RS, Rosing H, Mizuo H, Kawaguchi S, Critchley D, Shumaker R, Schellens JH, Beijnen JH. Metabolite profiling of the multiple tyrosine kinase inhibitor lenvatinib: a cross-species comparison. Investigational New Drugs. PMID 27018262 DOI: 10.1007/S10637-016-0342-Y  0.473
2016 Nijenhuis CM, Lucas L, Rosing H, Robertson P, Hellriegel ET, Schellens JH, Beijnen AJ. Metabolite profiling of (14)C-omacetaxine mepesuccinate in plasma and excreta of cancer patients. Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 1-11. PMID 26998885 DOI: 10.3109/00498254.2016.1152418  0.413
2016 Meulendijks D, de Groot JW, Los M, Boers JE, Beerepoot LV, Polee MB, Beeker A, Portielje JE, Goey SH, de Jong RS, Vanhoutvin SA, Kuiper M, Sikorska K, Pluim D, Beijnen JH, ... Schellens JH, et al. Bevacizumab combined with docetaxel, oxaliplatin, and capecitabine, followed by maintenance with capecitabine and bevacizumab, as first-line treatment of patients with advanced HER2-negative gastric cancer: A multicenter phase 2 study. Cancer. PMID 26970343 DOI: 10.1002/Cncr.29864  0.421
2016 van Brummelen EM, Huitema AD, van Werkhoven E, Beijnen JH, Schellens JH. The performance of model-based versus rule-based phase I clinical trials in oncology : A quantitative comparison of the performance of model-based versus rule-based phase I trials with molecularly targeted anticancer drugs over the last 2 years. Journal of Pharmacokinetics and Pharmacodynamics. PMID 26960536 DOI: 10.1007/S10928-016-9466-0  0.44
2016 Nijenhuis CM, Huitema AD, Marchetti S, Blank C, Haanen JB, van Thienen JV, Rosing H, Schellens JH, Beijnen JH. The use of Dried Blood Spots for Pharmacokinetic Monitoring of Vemurafenib Treatment in Melanoma Patients. Journal of Clinical Pharmacology. PMID 26918324 DOI: 10.1002/Jcph.728  0.453
2016 de Vries Schultink AH, Suleiman AA, Schellens JH, Beijnen JH, Huitema AD. Pharmacodynamic modeling of adverse effects of anti-cancer drug treatment. European Journal of Clinical Pharmacology. PMID 26915815 DOI: 10.1007/S00228-016-2030-4  0.471
2016 van Geel RM, Hendrikx JJ, Vahl JE, van Leerdam ME, van den Broek D, Huitema AD, Beijnen JH, Schellens JH, Burgers SA. Crizotinib-induced fatal fulminant liver failure. Lung Cancer (Amsterdam, Netherlands). 93: 17-9. PMID 26898609 DOI: 10.1016/J.Lungcan.2015.12.010  0.382
2016 Sparidans RW, van Hoppe S, Rood JJ, Schinkel AH, Schellens JH, Beijnen JH. Liquid chromatography-tandem mass spectrometric assay for the tyrosine kinase inhibitor afatinib in mouse plasma using salting-out liquid-liquid extraction. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 1012: 118-123. PMID 26826475 DOI: 10.1016/J.Jchromb.2016.01.025  0.473
2016 Meulendijks D, Henricks LM, Amstutz U, Froehlich TK, Largiadèr CR, Beijnen JH, de Boer A, Deenen MJ, Cats A, Schellens JH. Rs895819 in MIR27A improves the predictive value of DPYD variants to identify patients at risk of severe fluoropyrimidine-associated toxicity. International Journal of Cancer. Journal International Du Cancer. PMID 26804235 DOI: 10.1002/Ijc.30014  0.39
2016 Kip AE, Rosing H, Hillebrand MJ, Blesson S, Mengesha B, Diro E, Hailu A, Schellens JH, Beijnen JH, Dorlo TP. Validation and clinical evaluation of a novel method to measure miltefosine in leishmaniasis patients using dried blood spot sample collection. Antimicrobial Agents and Chemotherapy. PMID 26787691 DOI: 10.1128/Aac.02976-15  0.431
2016 Meulendijks D, van Hasselt JG, Huitema AD, van Tinteren H, Deenen MJ, Beijnen JH, Cats A, Schellens JH. Renal function, body surface area, and age are associated with risk of early-onset fluoropyrimidine-associated toxicity in patients treated with capecitabine-based anticancer regimens in daily clinical care. European Journal of Cancer (Oxford, England : 1990). 54: 120-130. PMID 26761784 DOI: 10.1016/J.Ejca.2015.10.013  0.672
2016 Crombag MR, Joerger M, Thürlimann B, Schellens JH, Beijnen JH, Huitema AD. Pharmacokinetics of Selected Anticancer Drugs in Elderly Cancer Patients: Focus on Breast Cancer. Cancers. 8. PMID 26729170 DOI: 10.3390/Cancers8010006  0.458
2015 Derissen EJ, Jacobs BA, Huitema AD, Rosing H, Schellens JH, Beijnen JH. Exploring the intracellular pharmacokinetics of the 5-fluorouracil nucleotides during capecitabine treatment. British Journal of Clinical Pharmacology. PMID 26718616 DOI: 10.1111/Bcp.12877  0.42
2015 Verheijen RB, Bins S, Thijssen B, Rosing H, Nan L, Schellens JH, Mathijssen RH, Lolkema MP, Beijnen JH, Steeghs N, Huitema AD. Development and clinical validation of an LC-MS/MS method for the quantification of pazopanib in DBS. Bioanalysis. PMID 26652864 DOI: 10.4155/Bio.15.235  0.451
2015 Meulendijks D, Beerepoot LV, Boot H, de Groot JW, Los M, Boers JE, Vanhoutvin SA, Polee MB, Beeker A, Portielje JE, de Jong RS, Goey SH, Kuiper M, Sikorska K, Beijnen JH, ... ... Schellens JH, et al. Trastuzumab and bevacizumab combined with docetaxel, oxaliplatin and capecitabine as first-line treatment of advanced HER2-positive gastric cancer: a multicenter phase II study. Investigational New Drugs. PMID 26643663 DOI: 10.1007/S10637-015-0309-4  0.429
2015 van Geel RM, Beijnen JH, Bernards R, Schellens JH. Treatment Individualization in Colorectal Cancer. Current Colorectal Cancer Reports. 11: 335-344. PMID 26617477 DOI: 10.1007/S11888-015-0288-Z  0.42
2015 Meulendijks D, Henricks LM, Sonke GS, Deenen MJ, Froehlich TK, Amstutz U, Largiadèr CR, Jennings BA, Marinaki AM, Sanderson JD, Kleibl Z, Kleiblova P, Schwab M, Zanger UM, Palles C, ... ... Schellens JH, et al. Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data. The Lancet. Oncology. PMID 26603945 DOI: 10.1016/S1470-2045(15)00286-7  0.36
2015 Yu H, Hendrikx JJ, Rottenberg S, Schellens JH, Beijnen JH, Huitema AD. Development of a Tumour Growth Inhibition Model to Elucidate the Effects of Ritonavir on Intratumoural Metabolism and Anti-tumour Effect of Docetaxel in a Mouse Model for Hereditary Breast Cancer. The Aaps Journal. PMID 26603889 DOI: 10.1208/S12248-015-9838-1  0.434
2015 Munster PN, Aggarwal R, Hong D, Schellens JH, van der Noll R, Specht J, Witteveen PO, Werner T, Dees EC, Bergsland EK, Agarwal N, Kleha JF, Durante M, Adams LM, Smith DA, et al. First-in-human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-kinase inhibitor, in Patients with Advanced Solid Tumor Malignancies. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26603258 DOI: 10.1158/1078-0432.Ccr-15-1665  0.302
2015 Deenen MJ, Meulendijks D, Cats A, Sechterberger MK, Severens JL, Boot H, Smits PH, Rosing H, Mandigers CM, Soesan M, Beijnen JH, Schellens JH. Upfront Genotyping of DPYD*2A to Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26573078 DOI: 10.1200/Jco.2015.63.1325  0.401
2015 Milojkovic Kerklaan B, Pluim D, Bol M, Hofland I, Westerga J, van Tinteren H, Beijnen JH, Boogerd W, Schellens JH, Brandsma D. EpCAM-based flow cytometry in cerebrospinal fluid greatly improves diagnostic accuracy of leptomeningeal metastases from epithelial tumors. Neuro-Oncology. PMID 26566655 DOI: 10.1093/Neuonc/Nov273  0.378
2015 Henricks LM, Schellens JH, Huitema AD, Beijnen JH. The use of combinations of monoclonal antibodies in clinical oncology. Cancer Treatment Reviews. PMID 26547132 DOI: 10.1016/J.Ctrv.2015.10.008  0.41
2015 Rood JJ, van Hoppe S, Schinkel AH, Schellens JH, Beijnen JH, Sparidans RW. Liquid chromatography-tandem mass spectrometric assay for the simultaneous determination of the irreversible BTK inhibitor ibrutinib and its dihydrodiol-metabolite in plasma and its application in mouse pharmacokinetic studies. Journal of Pharmaceutical and Biomedical Analysis. 118: 123-131. PMID 26540627 DOI: 10.1016/J.Jpba.2015.10.033  0.471
2015 Keusters WR, Frederix GW, de Weger VA, Beijnen JH, Hövels AM, Schellens JH. Decrease of Patient Costs in the Netherlands: a Cost of Illness Study in Metastatic Non Small Cell Lung Cancer (Nsclc). Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 18: A446. PMID 26532512 DOI: 10.1016/J.Jval.2015.09.1113  0.377
2015 Deenen MJ, Meulendijks D, Boot H, Legdeur MJ, Beijnen JH, Schellens JH, Cats A. Phase 1a/1b and pharmacogenetic study of docetaxel, oxaliplatin and capecitabine in patients with advanced cancer of the stomach or the gastroesophageal junction. Cancer Chemotherapy and Pharmacology. PMID 26499900 DOI: 10.1007/S00280-015-2872-Y  0.435
2015 Milojkovic Kerklaan B, van Tellingen O, Huitema AD, Beijnen JH, Boogerd W, Schellens JH, Brandsma D. Strategies to target drugs to gliomas and CNS metastases of solid tumors. Journal of Neurology. PMID 26477024 DOI: 10.1007/S00415-015-7919-9  0.397
2015 van der Noll R, Smit WM, Wymenga AN, Boss DS, Grob M, Huitema AD, Rosing H, Tibben MM, Keessen M, Rehorst H, Beijnen JH, Schellens JH. Phase I and pharmacological trial of lapatinib in combination with gemcitabine in patients with advanced breast cancer. Investigational New Drugs. PMID 26362459 DOI: 10.1007/S10637-015-0281-Z  0.493
2015 Nijenhuis CM, Lucas L, Rosing H, Schellens JH, Beijnen JH, Gorman SH, Burke SM, Campbell DA, Chapple MW, Yousey TH, Mulvana DE. Validation of high-performance liquid chromatography-tandem mass spectrometry assays quantifying omacetaxine mepesuccinate and its 4'‑des-methyl and cephalotaxine metabolites in human plasma and urine. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 1002: 152-9. PMID 26319804 DOI: 10.1016/J.Jchromb.2015.08.015  0.481
2015 van Hasselt J, Gupta A, Hussein Z, Beijnen JH, Schellens J, Huitema A. Disease Progression/Clinical Outcome Model for Castration-Resistant Prostate Cancer in Patients Treated With Eribulin. Cpt: Pharmacometrics & Systems Pharmacology. 4: 386-95. PMID 26312162 DOI: 10.1002/psp4.49  0.647
2015 van Hasselt J, Gupta A, Hussein Z, Beijnen JH, Schellens J, Huitema A. Integrated Simulation Framework for Toxicity, Dose Intensity, Disease Progression, and Cost Effectiveness for Castration-Resistant Prostate Cancer Treatment With Eribulin. Cpt: Pharmacometrics & Systems Pharmacology. 4: 374-85. PMID 26312161 DOI: 10.1002/psp4.48  0.658
2015 Hendrikx JJ, Lagas JS, Song JY, Rosing H, Schellens JH, Beijnen JH, Rottenberg S, Schinkel AH. Ritonavir inhibits intratumoral docetaxel metabolism and enhances docetaxel antitumor activity in an immunocompetent mouse breast cancer model. International Journal of Cancer. Journal International Du Cancer. PMID 26297509 DOI: 10.1002/Ijc.29812  0.447
2015 Kerklaan BM, Lolkema MP, Devriese LA, Voest EE, Nol-Boekel A, Mergui-Roelvink M, Langenberg M, Mykulowycz K, Stoebenau J, Lane S, Legenne P, Wissel P, Smith DA, Giantonio BJ, Schellens JH, et al. Phase I and pharmacological study of pazopanib in combination with oral topotecan in patients with advanced solid tumours. British Journal of Cancer. 113: 706-15. PMID 26291057 DOI: 10.1038/Bjc.2015.257  0.352
2015 Meulendijks D, Jacobs BA, Aliev A, Pluim D, van Werkhoven E, Deenen MJ, Beijnen JH, Cats A, Schellens JH. Increased risk of severe fluoropyrimidine-associated toxicity in patients carrying a G>C Substitution in the First 28-bp tandem repeat of the thymidylate synthase 2R Allele. International Journal of Cancer. Journal International Du Cancer. PMID 26189437 DOI: 10.1002/Ijc.29694  0.412
2015 van der Noll R, Marchetti S, Steeghs N, Beijnen JH, Mergui-Roelvink MW, Harms E, Rehorst H, Sonke GS, Schellens JH. Long-term safety and anti-tumour activity of olaparib monotherapy after combination with carboplatin and paclitaxel in patients with advanced breast, ovarian or fallopian tube cancer. British Journal of Cancer. 113: 396-402. PMID 26180927 DOI: 10.1038/Bjc.2015.256  0.415
2015 Kip AE, Rosing H, Hillebrand MJ, Castro MM, Gomez MA, Schellens JH, Beijnen JH, Dorlo TP. Quantification of miltefosine in peripheral blood mononuclear cells by high-performance liquid chromatography-tandem mass spectrometry. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 998: 57-62. PMID 26160472 DOI: 10.1016/J.Jchromb.2015.06.017  0.484
2015 Keizer RJ, Jansen RS, Rosing H, Thijssen B, Beijnen JH, Schellens JH, Huitema AD. Incorporation of concentration data below the limit of quantification in population pharmacokinetic analyses. Pharmacology Research & Perspectives. 3: e00131. PMID 26038706 DOI: 10.1002/Prp2.131  0.402
2015 Jager NG, Rosing H, Linn SC, Schellens JH, Beijnen JH. Dried blood spot self-sampling at home for the individualization of tamoxifen treatment: a feasibility study. Therapeutic Drug Monitoring. PMID 26035041 DOI: 10.1097/Ftd.0000000000000224  0.357
2015 Jager NG, Linn SC, Schellens JH, Beijnen JH. Tailored Tamoxifen Treatment for Breast Cancer Patients: A Perspective. Clinical Breast Cancer. PMID 25997856 DOI: 10.1016/J.Clbc.2015.04.005  0.473
2015 van Hasselt JG, Allegaert K, van Calsteren K, Beijnen JH, Schellens JH, Huitema AD. Corrigendum to "Semiphysiological versus Empirical Modelling of the Population Pharmacokinetics of Free and Total Cefazolin during Pregnancy". Biomed Research International. 2015: 124035. PMID 25922829 DOI: 10.1155/2015/124035  0.665
2015 Meulendijks D, Tomasoa NB, Dewit L, Smits PH, Bakker R, van Velthuysen ML, Rosenberg EH, Beijnen JH, Schellens JH, Cats A. HPV-negative squamous cell carcinoma of the anal canal is unresponsive to standard treatment and frequently carries disruptive mutations in TP53. British Journal of Cancer. 112: 1358-66. PMID 25871546 DOI: 10.1038/Bjc.2015.20  0.351
2015 Pluim D, Jacobs BA, Deenen MJ, Ruijter AE, van Geel RM, Burylo AM, Meulendijks D, Beijnen JH, Schellens JH. Improved pharmacodynamic assay for dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells. Bioanalysis. 7: 519-29. PMID 25826134 DOI: 10.4155/Bio.14.304  0.397
2015 Herbrink M, Nuijen B, Schellens JH, Beijnen JH. Variability in bioavailability of small molecular tyrosine kinase inhibitors. Cancer Treatment Reviews. 41: 412-422. PMID 25818541 DOI: 10.1016/J.Ctrv.2015.03.005  0.455
2015 Derissen EJ, Hillebrand MJ, Rosing H, Schellens JH, Beijnen JH. Development of an LC-MS/MS assay for the quantitative determination of the intracellular 5-fluorouracil nucleotides responsible for the anticancer effect of 5-fluorouracil. Journal of Pharmaceutical and Biomedical Analysis. 110: 58-66. PMID 25804433 DOI: 10.1016/J.Jpba.2015.02.051  0.468
2015 Joerger M, Huitema AD, Boot H, Cats A, Doodeman VD, Smits PH, Vainchtein L, Rosing H, Meijerman I, Zueger M, Meulendijks D, Cerny TD, Beijnen JH, Schellens JH. Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy. Cancer Chemotherapy and Pharmacology. 75: 763-72. PMID 25677447 DOI: 10.1007/S00280-015-2698-7  0.435
2015 Devriese LA, Witteveen PE, Mergui-Roelvink M, Smith DA, Lewis LD, Mendelson DS, Bang YJ, Chung HC, Dar MM, Huitema AD, Beijnen JH, Voest EE, Schellens JH. Pharmacodynamics and pharmacokinetics of oral topotecan in patients with advanced solid tumours and impaired renal function. British Journal of Clinical Pharmacology. PMID 25677219 DOI: 10.1111/Bcp.12606  0.433
2015 Dolman ME, Westerhout EM, Hamdi M, Schellens JH, Beijnen JH, Sparidans RW. Liquid chromatography-tandem mass spectrometric assay for the PI3K/mTOR inhibitor GSK2126458 in mouse plasma and tumor homogenate. Journal of Pharmaceutical and Biomedical Analysis. 107: 403-8. PMID 25659532 DOI: 10.1016/J.Jpba.2015.01.026  0.484
2015 Meulendijks D, Khan S, Koks CH, Huitema AD, Schellens JH, Beijnen JH. Baclofen overdose treated with continuous venovenous hemofiltration. European Journal of Clinical Pharmacology. 71: 357-61. PMID 25567218 DOI: 10.1007/S00228-014-1802-Y  0.392
2015 Frederix GW, Severens JL, Hövels AM, van Hasselt JG, Hooiveld MJ, Neven P, Raaijmakers JA, Schellens JH. Real world cost of human epidermal receptor 2-positive metastatic breast cancer patients: a longitudinal incidence-based observational costing study in the Netherlands and Belgium. European Journal of Cancer Care. 24: 340-54. PMID 25413216 DOI: 10.1111/Ecc.12266  0.621
2015 Yu H, Steeghs N, Kloth JS, de Wit D, van Hasselt JG, van Erp NP, Beijnen JH, Schellens JH, Mathijssen RH, Huitema AD. Integrated semi-physiological pharmacokinetic model for both sunitinib and its active metabolite SU12662. British Journal of Clinical Pharmacology. 79: 809-19. PMID 25393890 DOI: 10.1111/Bcp.12550  0.681
2015 Dubbelman AC, Rosing H, Nijenhuis C, Huitema AD, Mergui-Roelvink M, Gupta A, Verbel D, Thompson G, Shumaker R, Schellens JH, Beijnen JH. Pharmacokinetics and excretion of (14)C-lenvatinib in patients with advanced solid tumors or lymphomas. Investigational New Drugs. 33: 233-40. PMID 25377392 DOI: 10.1007/S10637-014-0181-7  0.496
2015 Kip AE, Balasegaram M, Beijnen JH, Schellens JH, de Vries PJ, Dorlo TP. Systematic review of biomarkers to monitor therapeutic response in leishmaniasis. Antimicrobial Agents and Chemotherapy. 59: 1-14. PMID 25367913 DOI: 10.1128/Aac.04298-14  0.42
2015 Leijen S, Burgers SA, Baas P, Pluim D, Tibben M, van Werkhoven E, Alessio E, Sava G, Beijnen JH, Schellens JH. Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy. Investigational New Drugs. 33: 201-14. PMID 25344453 DOI: 10.1007/S10637-014-0179-1  0.447
2015 Janssens T, Brouwers EE, de Vos JP, de Vries N, Schellens JH, Beijnen JH. Inductively coupled plasma mass-spectrometric determination of platinum in excretion products of client-owned pet dogs. Veterinary and Comparative Oncology. 13: 124-32. PMID 23714139 DOI: 10.1111/Vco.12025  0.438
2014 Joerger M, Huitema AD, Boot H, Cats A, Doodeman V, Smits P, Vainchtein L, Rosing H, Meijerman I, Zueger M, Cerny TT, Beijnen JH, Schellens J. 1577PGERMLINE TYMS GENOTYPE IS HIGHLY PREDICTIVE IN PATIENTS WITH ADVANCED COLORECTAL AND GASTROESOPHAGEAL CANCER INDEPENDENT OF FLUOROPYRIMIDINE PHARMACOLOGY: RESULTS FROM TWO PROSPECTIVE TRANSLATIONAL STUDIES. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 25: iv548. PMID 28172174 DOI: 10.1093/Annonc/Mdu358.8  0.485
2014 Juric D, Burris H, Schuler M, Schellens J, Berlin J, Seggewiß-Bernhardt R, Gil-Martin M, Gupta A, Rodon J, Tabernero J, Janku F, Rugo HS, Bootle D, Quadt C, Coughlin C, et al. 451PDPHASE I STUDY OF THE PI3Kα INHIBITOR BYL719, AS A SINGLE AGENT IN PATIENTS WITH ADVANCED SOLID TUMORS (AST). Annals of Oncology : Official Journal of the European Society For Medical Oncology. 25: iv150. PMID 28170787 DOI: 10.1093/Annonc/Mdu331.11  0.33
2014 Nijenhuis CM, Rosing H, Schellens JH, Beijnen JH. Quantifying vemurafenib in dried blood spots using high-performance LC-MS/MS. Bioanalysis. 6: 3215-24. PMID 25529888 DOI: 10.4155/Bio.14.171  0.406
2014 Jager NG, Rosing H, Schellens JH, Beijnen JH. Determination of tamoxifen and endoxifen in dried blood spots using LC-MS/MS and the effect of coated DBS cards on recovery and matrix effects. Bioanalysis. 6: 2999-3009. PMID 25496254 DOI: 10.4155/Bio.14.157  0.309
2014 Jager NG, Rosing H, Schellens JH, Beijnen JH. Procedures and practices for the validation of bioanalytical methods using dried blood spots: a review. Bioanalysis. 6: 2481-514. PMID 25384597 DOI: 10.4155/Bio.14.185  0.41
2014 Moreno García V, Olmos D, Gomez-Roca C, Cassier PA, Morales-Barrera R, Del Conte G, Gallerani E, Brunetto AT, Schöffski P, Marsoni S, Schellens JH, Penel N, Voest E, Evans J, Plummer R, et al. Dose-response relationship in phase i clinical trials: a European Drug Development Network (EDDN) Collaboration Study. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 5663-71. PMID 25252757 DOI: 10.1200/Jco.2011.29.15_Suppl.3084  0.369
2014 Crombag MR, de Vries Schultink AH, Schellens JH, Beijnen JH, Huitema AD. Incidence of hematologic toxicity in older adults treated with gemcitabine or a gemcitabine-containing regimen in routine clinical practice: a multicenter retrospective cohort study. Drugs & Aging. 31: 737-47. PMID 25216600 DOI: 10.1007/S40266-014-0207-Z  0.389
2014 van Hasselt JG, van Eijkelenburg NK, Beijnen JH, Schellens JH, Huitema AD. Design of a drug-drug interaction study of vincristine with azole antifungals in pediatric cancer patients using clinical trial simulation. Pediatric Blood & Cancer. 61: 2223-9. PMID 25175364 DOI: 10.1002/Pbc.25198  0.676
2014 Meulendijks D, Dewit L, Tomasoa NB, van Tinteren H, Beijnen JH, Schellens JH, Cats A. Chemoradiotherapy with capecitabine for locally advanced anal carcinoma: an alternative treatment option. British Journal of Cancer. 111: 1726-33. PMID 25167226 DOI: 10.1038/Bjc.2014.467  0.394
2014 Opdam FL, Huitema AD, Beijnen JH, Schellens JH. [Hyperglycaemia during treatment with everolimus]. Nederlands Tijdschrift Voor Geneeskunde. 158: A7544. PMID 25115206  0.313
2014 Marchetti S, Pluim D, Beijnen JH, Mazzanti R, van Tellingen O, Schellens JH. "Effect of the drug transporters ABCB1, ABCC2, and ABCG2 on the disposition and brain accumulation of the taxane analog BMS-275,183". Investigational New Drugs. 32: 1083-95. PMID 25078948 DOI: 10.1007/S10637-014-0143-0  0.459
2014 Zimmer L, Barlesi F, Martinez-Garcia M, Dieras V, Schellens JH, Spano JP, Middleton MR, Calvo E, Paz-Ares L, Larkin J, Pacey S, Venturi M, Kraeber-Bodéré F, Tessier JJ, Eberhardt WE, et al. Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 4251-61. PMID 24947927 DOI: 10.1158/1078-0432.Ccr-14-0341  0.313
2014 Jager NG, Rosing H, Schellens JH, Beijnen JH, Linn SC. Use of dried blood spots for the determination of serum concentrations of tamoxifen and endoxifen. Breast Cancer Research and Treatment. 146: 137-44. PMID 24859000 DOI: 10.1007/S10549-014-2999-2  0.403
2014 Hendrikx JJ, Rosing H, Schinkel AH, Schellens JH, Beijnen JH. Quantification of taxanes in biological matrices: a review of bioanalytical assays and recommendations for development of new assays. Bioanalysis. 6: 993-1010. PMID 24806907 DOI: 10.4155/Bio.14.48  0.445
2014 van Hasselt JG, Schellens JH, Beijnen JH, Huitema AD. Design of informative renal impairment studies: evaluation of the impact of design stratification on bias, precision and dose adjustment error. Investigational New Drugs. 32: 913-27. PMID 24788562 DOI: 10.1007/S10637-014-0103-8  0.668
2014 Hendrikx JJ, Lagas JS, Wagenaar E, Rosing H, Schellens JH, Beijnen JH, Schinkel AH. Oral co-administration of elacridar and ritonavir enhances plasma levels of oral paclitaxel and docetaxel without affecting relative brain accumulation. British Journal of Cancer. 110: 2669-76. PMID 24781280 DOI: 10.1038/Bjc.2014.222  0.448
2014 Lankheet NA, Kloth JS, Gadellaa-van Hooijdonk CG, Cirkel GA, Mathijssen RH, Lolkema MP, Schellens JH, Voest EE, Sleijfer S, de Jonge MJ, Haanen JB, Beijnen JH, Huitema AD, Steeghs N. Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours. British Journal of Cancer. 110: 2441-9. PMID 24736581 DOI: 10.1038/Bjc.2014.194  0.477
2014 Mooiman KD, Goey AK, Huijbregts TJ, Maas-Bakker RF, Beijnen JH, Schellens JH, Meijerman I. The in-vitro effect of complementary and alternative medicines on cytochrome P450 2C9 activity. The Journal of Pharmacy and Pharmacology. 66: 1339-46. PMID 24730468 DOI: 10.1111/Jphp.12259  0.464
2014 Hendrikx JJ, Lagas JS, Daling R, Hooijberg JH, Schellens JH, Beijnen JH, Brandjes DP, Huitema AD. Severe lactic acidosis in a diabetic patient after ethanol abuse and floor cleaner intake. Basic & Clinical Pharmacology & Toxicology. 115: 472-5. PMID 24717115 DOI: 10.1111/Bcpt.12251  0.367
2014 van Hasselt JG, van Calsteren K, Heyns L, Han S, Mhallem Gziri M, Schellens JH, Beijnen JH, Huitema AD, Amant F. Optimizing anticancer drug treatment in pregnant cancer patients: pharmacokinetic analysis of gestation-induced changes for doxorubicin, epirubicin, docetaxel and paclitaxel. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 25: 2059-65. PMID 24713311 DOI: 10.1093/Annonc/Mdu140  0.701
2014 van Hasselt JG, Allegaert K, van Calsteren K, Beijnen JH, Schellens JH, Huitema AD. Semiphysiological versus empirical modelling of the population pharmacokinetics of free and total cefazolin during pregnancy. Biomed Research International. 2014: 897216. PMID 24672799 DOI: 10.1155/2014/897216  0.662
2014 Goey AK, Beijnen JH, Schellens JH. Herb-drug interactions in oncology. Clinical Pharmacology and Therapeutics. 95: 354-5. PMID 24646483 DOI: 10.1038/Clpt.2014.18  0.4
2014 de Weger VA, Beijnen JH, Schellens JH. Cellular and clinical pharmacology of the taxanes docetaxel and paclitaxel--a review. Anti-Cancer Drugs. 25: 488-94. PMID 24637579 DOI: 10.1097/Cad.0000000000000093  0.479
2014 Luethi D, Durmus S, Schinkel AH, Schellens JH, Beijnen JH, Sparidans RW. Liquid chromatography-tandem mass spectrometric assay for the multikinase inhibitor regorafenib in plasma. Biomedical Chromatography : Bmc. 28: 1366-70. PMID 24619951 DOI: 10.1002/Bmc.3176  0.491
2014 Yu H, Steeghs N, Nijenhuis CM, Schellens JH, Beijnen JH, Huitema AD. Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targets. Clinical Pharmacokinetics. 53: 305-25. PMID 24566736 DOI: 10.1007/S40262-014-0137-2  0.469
2014 Dolman ME, den Hartog IJ, Molenaar JJ, Schellens JH, Beijnen JH, Sparidans RW. Liquid chromatography-tandem mass spectrometric assay for the light sensitive survivin suppressant sepantronium bromide (YM155) in mouse plasma. Journal of Pharmaceutical and Biomedical Analysis. 92: 144-8. PMID 24518133 DOI: 10.1016/J.Jpba.2014.01.011  0.474
2014 Mooiman KD, Maas-Bakker RF, Hendrikx JJ, Bank PC, Rosing H, Beijnen JH, Schellens JH, Meijerman I. The effect of complementary and alternative medicines on CYP3A4-mediated metabolism of three different substrates: 7-benzyloxy-4-trifluoromethyl-coumarin, midazolam and docetaxel. The Journal of Pharmacy and Pharmacology. 66: 865-74. PMID 24392691 DOI: 10.1111/Jphp.12208  0.446
2014 Jager NG, Rosing H, Schellens JH, Linn SC, Beijnen JH. Tamoxifen dose and serum concentrations of tamoxifen and six of its metabolites in routine clinical outpatient care. Breast Cancer Research and Treatment. 143: 477-83. PMID 24390246 DOI: 10.1007/S10549-013-2826-1  0.483
2014 Vlaming ML, Teunissen SF, van de Steeg E, van Esch A, Wagenaar E, Brunsveld L, de Greef TF, Rosing H, Schellens JH, Beijnen JH, Schinkel AH. Bcrp1;Mdr1a/b;Mrp2 combination knockout mice: altered disposition of the dietary carcinogen PhIP (2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine) and its genotoxic metabolites. Molecular Pharmacology. 85: 520-30. PMID 24334255 DOI: 10.1124/Mol.113.088823  0.406
2014 Derissen EJ, Hillebrand MJ, Rosing H, Otten HM, Laille E, Schellens JH, Beijnen JH. Quantitative determination of azacitidine triphosphate in peripheral blood mononuclear cells using liquid chromatography coupled with high-resolution mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis. 90: 7-14. PMID 24317024 DOI: 10.1016/J.Jpba.2013.11.010  0.457
2014 Meulenaar J, Keizer RJ, Beijnen JH, Schellens JH, Huitema AD, Nuijen B. Development of an extended-release formulation of capecitabine making use of in vitro-in vivo correlation modelling. Journal of Pharmaceutical Sciences. 103: 478-84. PMID 24311366 DOI: 10.1002/Jps.23779  0.408
2014 Lankheet NA, Knapen LM, Schellens JH, Beijnen JH, Steeghs N, Huitema AD. Plasma concentrations of tyrosine kinase inhibitors imatinib, erlotinib, and sunitinib in routine clinical outpatient cancer care. Therapeutic Drug Monitoring. 36: 326-34. PMID 24305627 DOI: 10.1097/Ftd.0000000000000004  0.44
2014 Frederix GW, van Hasselt JG, Schellens JH, Hövels AM, Raaijmakers JA, Huitema AD, Severens JL. The impact of structural uncertainty on cost-effectiveness models for adjuvant endocrine breast cancer treatments: the need for disease-specific model standardization and improved guidance. Pharmacoeconomics. 32: 47-61. PMID 24263964 DOI: 10.1007/S40273-013-0106-X  0.626
2014 Kloth JS, Klümpen HJ, Yu H, Eechoute K, Samer CF, Kam BL, Huitema AD, Daali Y, Zwinderman AH, Balakrishnar B, Bennink RJ, Wong M, Schellens JH, Mathijssen RH, Gurney H. Predictive value of CYP3A and ABCB1 phenotyping probes for the pharmacokinetics of sunitinib: the ClearSun study. Clinical Pharmacokinetics. 53: 261-9. PMID 24234588 DOI: 10.1007/S40262-013-0111-4  0.347
2014 Helgason HH, Koolen SL, Werkhoven Ev, Malingre MM, Kruijtzer CM, Huitema AD, Schot ME, Smit WM, Beijnen JH, Schellens JH. Phase II and pharmacological study of oral docetaxel plus cyclosporin A in anthracycline pre-treated metastatic breast cancer. Current Clinical Pharmacology. 9: 139-47. PMID 24219005 DOI: 10.2174/1574884708666131111193403  0.445
2014 Nijenhuis CM, Rosing H, Schellens JH, Beijnen JH. Development and validation of a high-performance liquid chromatography-tandem mass spectrometry assay quantifying vemurafenib in human plasma. Journal of Pharmaceutical and Biomedical Analysis. 88: 630-5. PMID 24216282 DOI: 10.1016/J.Jpba.2013.10.019  0.491
2014 Sparidans RW, Durmus S, Schinkel AH, Schellens JH, Beijnen JH. Liquid chromatography-tandem mass spectrometric assay for the PARP inhibitor rucaparib in plasma. Journal of Pharmaceutical and Biomedical Analysis. 88: 626-9. PMID 24216281 DOI: 10.1016/J.Jpba.2013.10.016  0.477
2014 Joerger M, Huitema AD, Koeberle D, Rosing H, Beijnen JH, Hitz F, Cerny T, Schellens JH, Gillessen S. Safety and pharmacology of gemcitabine and capecitabine in patients with advanced pancreatico-biliary cancer and hepatic dysfunction. Cancer Chemotherapy and Pharmacology. 73: 113-24. PMID 24166106 DOI: 10.1007/S00280-013-2327-2  0.488
2014 Dolman ME, den Hartog IJ, Molenaar JJ, Schellens JH, Beijnen JH, Sparidans RW. Liquid chromatography-tandem mass spectrometric assay for the cyclin-dependent kinase inhibitor AT7519 in mouse plasma. Journal of Pharmaceutical and Biomedical Analysis. 88: 216-20. PMID 24080524 DOI: 10.1016/J.Jpba.2013.08.051  0.48
2014 Goey AK, Meijerman I, Rosing H, Marchetti S, Mergui-Roelvink M, Keessen M, Burgers JA, Beijnen JH, Schellens JH. The effect of St John's wort on the pharmacokinetics of docetaxel. Clinical Pharmacokinetics. 53: 103-10. PMID 24068654 DOI: 10.1007/S40262-013-0102-5  0.493
2014 Hendrikx JJ, Rosing H, Schinkel AH, Schellens JH, Beijnen JH. Combined quantification of paclitaxel, docetaxel and ritonavir in human feces and urine using LC-MS/MS. Biomedical Chromatography : Bmc. 28: 302-10. PMID 23996474 DOI: 10.1002/Bmc.3021  0.497
2013 Moes JJ, Stuurman FE, Hendrikx JJ, Marchetti S, Huitema AD, Beijnen JH, Schellens JH, Nuijen B. Pharmacokinetic evaluation of three oral formulations of docetaxel boosted with ritonavir: two single-drug formulations vs. a fixed-dose combination tablet. Drug Delivery and Translational Research. 3: 243-51. PMID 25788133 DOI: 10.1007/S13346-012-0127-6  0.492
2013 Jager NG, Koornstra RH, Vincent AD, van Schaik RH, Huitema AD, Korse TM, Schellens JH, Linn SC, Beijnen JH. Hot flashes are not predictive for serum concentrations of tamoxifen and its metabolites. Bmc Cancer. 13: 612. PMID 24373320 DOI: 10.1186/1471-2407-13-612  0.43
2013 Nijenhuis CM, Lucas L, Rosing H, Schellens JH, Beijnen JH. Development and validation of a high-performance liquid chromatography-tandem mass spectrometry assay quantifying olaparib in human plasma. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 940: 121-5. PMID 24145016 DOI: 10.1016/J.Jchromb.2013.09.020  0.489
2013 Janssens T, Brouwers EE, de Vos JP, de Vries N, Schellens JH, Beijnen JH. Determination of platinum surface contamination in veterinary and human oncology centres using inductively coupled plasma mass spectrometry. Veterinary and Comparative Oncology. PMID 24034226 DOI: 10.1111/Vco.12049  0.449
2013 Lankheet NA, Huitema AD, Mallo H, Adriaansz S, Haanen JB, Schellens JH, Beijnen JH, Blank CU. The effect of seasonal variation and secretion of sunitinib in sweat on the development of hand-foot syndrome. European Journal of Clinical Pharmacology. 69: 2065-72. PMID 23995862 DOI: 10.1007/S00228-013-1579-4  0.429
2013 Hendrikx JJ, Dubbelman AC, Rosing H, Schinkel AH, Schellens JH, Beijnen JH. Quantification of docetaxel and its metabolites in human plasma by liquid chromatography/tandem mass spectrometry. Rapid Communications in Mass Spectrometry : Rcm. 27: 1925-34. PMID 23939959 DOI: 10.1002/Rcm.6654  0.457
2013 Luethi D, Durmus S, Schinkel AH, Schellens JH, Beijnen JH, Sparidans RW. Liquid chromatography-tandem mass spectrometry assay for the EGFR inhibitor pelitinib in plasma. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 934: 22-5. PMID 23892825 DOI: 10.1016/J.Jchromb.2013.06.030  0.474
2013 Goey AK, Meijerman I, Beijnen JH, Schellens JH. The effect of grape seed extract on the pharmacokinetics of dextromethorphan in healthy volunteers. European Journal of Clinical Pharmacology. 69: 1883-90. PMID 23881421 DOI: 10.1007/S00228-013-1558-9  0.428
2013 Lau C, Mooiman KD, Maas-Bakker RF, Beijnen JH, Schellens JH, Meijerman I. Effect of Chinese herbs on CYP3A4 activity and expression in vitro. Journal of Ethnopharmacology. 149: 543-9. PMID 23876595 DOI: 10.1016/J.Jep.2013.07.014  0.473
2013 Stuurman FE, Lolkema MP, Huitema AD, Soetekouw PM, Rosing H, Rolfe L, Kaur P, Beijnen JH, van Tinteren H, Voest EE, Schellens JH. A phase 1 comparative pharmacokinetic and cardiac safety study of two intravenous formulations of CO-101 in patients with advanced solid tumors. Journal of Clinical Pharmacology. 53: 878-83. PMID 23775853 DOI: 10.1002/Jcph.108  0.42
2013 Goey AK, Meijerman I, Rosing H, Burgers JA, Mergui-Roelvink M, Keessen M, Marchetti S, Beijnen JH, Schellens JH. The effect of Echinacea purpurea on the pharmacokinetics of docetaxel. British Journal of Clinical Pharmacology. 76: 467-74. PMID 23701184 DOI: 10.1111/Bcp.12159  0.482
2013 Mooiman KD, Maas-Bakker RF, Moret EE, Beijnen JH, Schellens JH, Meijerman I. Milk thistle's active components silybin and isosilybin: novel inhibitors of PXR-mediated CYP3A4 induction. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 41: 1494-504. PMID 23674609 DOI: 10.1124/Dmd.113.050971  0.466
2013 Mooiman KD, Maas-Bakker RF, Rosing H, Beijnen JH, Schellens JH, Meijerman I. Development and validation of a LC-MS/MS method for the in vitro analysis of 1-hydroxymidazolam in human liver microsomes: application for determining CYP3A4 inhibition in complex matrix mixtures. Biomedical Chromatography : Bmc. 27: 1107-16. PMID 23674377 DOI: 10.1002/Bmc.2913  0.446
2013 Derissen EJ, Beijnen JH, Schellens JH. Concise drug review: azacitidine and decitabine. The Oncologist. 18: 619-24. PMID 23671007 DOI: 10.1634/Theoncologist.2012-0465  0.409
2013 Leijen S, Veltkamp SA, Huitema AD, van Werkhoven E, Beijnen JH, Schellens JH. Phase I dose-escalation study and population pharmacokinetic analysis of fixed dose rate gemcitabine plus carboplatin as second-line therapy in patients with ovarian cancer. Gynecologic Oncology. 130: 511-7. PMID 23665458 DOI: 10.1016/J.Ygyno.2013.05.001  0.48
2013 Jibodh RA, Lagas JS, Nuijen B, Beijnen JH, Schellens JH. Taxanes: old drugs, new oral formulations. European Journal of Pharmacology. 717: 40-6. PMID 23660368 DOI: 10.1016/J.Ejphar.2013.02.058  0.476
2013 Frederix GW, Severens JL, Hövels AM, van Hasselt JG, Raaijmakers JA, Schellens JH. Time-dependent resource use and costs associated with different states of disease in patients diagnosed with HER-2-positive metastatic breast cancer. Breast Cancer Research and Treatment. 139: 489-95. PMID 23645005 DOI: 10.1007/S10549-013-2532-Z  0.608
2013 van Hasselt JG, Gupta A, Hussein Z, Beijnen JH, Schellens JH, Huitema AD. Population pharmacokinetic-pharmacodynamic analysis for eribulin mesilate-associated neutropenia. British Journal of Clinical Pharmacology. 76: 412-24. PMID 23601153 DOI: 10.1111/Bcp.12143  0.702
2013 van Hasselt JG, van Eijkelenburg NK, Huitema AD, Schellens JH, Schouten-van Meeteren AY. Severe skin toxicity in pediatric oncology patients treated with voriconazole and concomitant methotrexate. Antimicrobial Agents and Chemotherapy. 57: 2878-81. PMID 23571545 DOI: 10.1128/Aac.00068-13  0.635
2013 Kort A, Hillebrand MJ, Cirkel GA, Voest EE, Schinkel AH, Rosing H, Schellens JH, Beijnen JH. Quantification of cabazitaxel, its metabolite docetaxel and the determination of the demethylated metabolites RPR112698 and RPR123142 as docetaxel equivalents in human plasma by liquid chromatography-tandem mass spectrometry. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 925: 117-23. PMID 23542607 DOI: 10.1016/J.Jchromb.2013.02.034  0.418
2013 Sparidans RW, Durmus S, Schinkel AH, Schellens JH, Beijnen JH. Liquid chromatography-tandem mass spectrometric assay for the mutated BRAF inhibitor dabrafenib in mouse plasma. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 925: 124-8. PMID 23537694 DOI: 10.1016/J.Jchromb.2013.02.025  0.473
2013 Deenen MJ, Dewit L, Boot H, Beijnen JH, Schellens JH, Cats A. Simultaneous integrated boost-intensity modulated radiation therapy with concomitant capecitabine and mitomycin C for locally advanced anal carcinoma: a phase 1 study. International Journal of Radiation Oncology, Biology, Physics. 85: e201-7. PMID 23517808 DOI: 10.1016/J.Ijrobp.2012.12.008  0.456
2013 Frederix GW, van Hasselt JG, Severens JL, Hövels AM, Huitema AD, Raaijmakers JA, Schellens JH. Development of a framework for cohort simulation in cost-effectiveness analyses using a multistep ordinary differential equation solver algorithm in R. Medical Decision Making : An International Journal of the Society For Medical Decision Making. 33: 780-92. PMID 23515213 DOI: 10.1177/0272989X13476763  0.607
2013 Lankheet NA, Steeghs N, Rosing H, Schellens JH, Beijnen JH, Huitema AD. Quantification of sunitinib and N-desethyl sunitinib in human EDTA plasma by liquid chromatography coupled with electrospray ionization tandem mass spectrometry: validation and application in routine therapeutic drug monitoring. Therapeutic Drug Monitoring. 35: 168-76. PMID 23503442 DOI: 10.1097/Ftd.0B013E31827Efd9E  0.489
2013 da Rocha Dias S, Salmonson T, van Zwieten-Boot B, Jonsson B, Marchetti S, Schellens JH, Giuliani R, Pignatti F. The European Medicines Agency review of vemurafenib (Zelboraf®) for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma: summary of the scientific assessment of the Committee for Medicinal Products for Human Use. European Journal of Cancer (Oxford, England : 1990). 49: 1654-61. PMID 23481513 DOI: 10.1016/J.Ejca.2013.01.015  0.322
2013 Lin F, Marchetti S, Pluim D, Iusuf D, Mazzanti R, Schellens JH, Beijnen JH, van Tellingen O. Abcc4 together with abcb1 and abcg2 form a robust cooperative drug efflux system that restricts the brain entry of camptothecin analogues. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 2084-95. PMID 23461902 DOI: 10.1158/1078-0432.Ccr-12-3105  0.421
2013 van der Noll R, Leijen S, Neuteboom GH, Beijnen JH, Schellens JH. Effect of inhibition of the FGFR-MAPK signaling pathway on the development of ocular toxicities. Cancer Treatment Reviews. 39: 664-72. PMID 23434072 DOI: 10.1016/J.Ctrv.2013.01.003  0.431
2013 Stuurman FE, Nuijen B, Beijnen JH, Schellens JH. Oral anticancer drugs: mechanisms of low bioavailability and strategies for improvement. Clinical Pharmacokinetics. 52: 399-414. PMID 23420518 DOI: 10.1007/S40262-013-0040-2  0.476
2013 Goey AK, Mooiman KD, Beijnen JH, Schellens JH, Meijerman I. Relevance of in vitro and clinical data for predicting CYP3A4-mediated herb-drug interactions in cancer patients. Cancer Treatment Reviews. 39: 773-83. PMID 23394826 DOI: 10.1016/J.Ctrv.2012.12.008  0.476
2013 Deenen MJ, Cats A, Beijnen JH, Schellens JH. Standard-dose tegafur-uracil (UFT) is not a safe alternative in partial dihydropyrimidine dehydrogenase-deficient patients. Therapeutic Advances in Medical Oncology. 5: 91-2. PMID 23323150 DOI: 10.1177/1758834012464806  0.452
2013 Dubbelman AC, Rosing H, Darwish M, D'Andrea D, Bond M, Hellriegel E, Robertson P, Beijnen JH, Schellens JH. Pharmacokinetics and excretion of 14C-bendamustine in patients with relapsed or refractory malignancy. Drugs in R&D. 13: 17-28. PMID 23322528 DOI: 10.1007/S40268-012-0001-5  0.512
2013 Pluim D, Jacobs BA, Krähenbühl MD, Ruijter AE, Beijnen JH, Schellens JH. Correction of peripheral blood mononuclear cell cytosolic protein for hemoglobin contamination. Analytical and Bioanalytical Chemistry. 405: 2391-5. PMID 23318760 DOI: 10.1007/S00216-012-6614-2  0.391
2013 Pluim D, Schilders KA, Jacobs BA, Vaartjes D, Beijnen JH, Schellens JH. Pharmacodynamic assay of thymidylate synthase activity in peripheral blood mononuclear cells. Analytical and Bioanalytical Chemistry. 405: 2495-503. PMID 23314484 DOI: 10.1007/S00216-012-6676-1  0.41
2013 Deenen MJ, Rosing H, Hillebrand MJ, Schellens JH, Beijnen JH. Quantitative determination of capecitabine and its six metabolites in human plasma using liquid chromatography coupled to electrospray tandem mass spectrometry. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 913: 30-40. PMID 23270936 DOI: 10.1016/J.Jchromb.2012.11.033  0.503
2013 Meulenaar J, Beijnen JH, Schellens JH, Nuijen B. Slow dissolution behaviour of amorphous capecitabine. International Journal of Pharmaceutics. 441: 213-7. PMID 23219704 DOI: 10.1016/J.Ijpharm.2012.11.041  0.391
2013 Hendrikx JJ, Lagas JS, Rosing H, Schellens JH, Beijnen JH, Schinkel AH. P-glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel. International Journal of Cancer. Journal International Du Cancer. 132: 2439-47. PMID 23090875 DOI: 10.1002/Ijc.27912  0.421
2013 Milojkovic Kerklaan B, Kerklaan BM, Diéras V, Le Tourneau C, Mergui-Roelvink M, Huitema AD, Rosing H, Beijnen JH, Marreaud S, Govaerts AS, Piccart-Gebhart MJ, Schellens JH, Awada A. Phase I study of lonafarnib (SCH66336) in combination with trastuzumab plus paclitaxel in Her2/neu overexpressing breast cancer: EORTC study 16023. Cancer Chemotherapy and Pharmacology. 71: 53-62. PMID 23053259 DOI: 10.1007/s00280-012-1972-1  0.383
2013 Lankheet NA, Hillebrand MJ, Rosing H, Schellens JH, Beijnen JH, Huitema AD. Method development and validation for the quantification of dasatinib, erlotinib, gefitinib, imatinib, lapatinib, nilotinib, sorafenib and sunitinib in human plasma by liquid chromatography coupled with tandem mass spectrometry. Biomedical Chromatography : Bmc. 27: 466-76. PMID 22987603 DOI: 10.1002/Bmc.2814  0.494
2013 Devriese LA, Witteveen PE, Wanders J, Law K, Edwards G, Reyderman L, Copalu W, Peng F, Marchetti S, Beijnen JH, Huitema AD, Voest EE, Schellens JH. Pharmacokinetics of eribulin mesylate in patients with solid tumours receiving repeated oral rifampicin. British Journal of Clinical Pharmacology. 75: 507-15. PMID 22803519 DOI: 10.1111/J.1365-2125.2012.04381.X  0.503
2013 Moes J, Koolen S, Huitema A, Schellens J, Beijnen J, Nuijen B. Development of an oral solid dispersion formulation for use in low-dose metronomic chemotherapy of paclitaxel European Journal of Pharmaceutics and Biopharmaceutics. 83: 87-94. DOI: 10.1016/J.Ejpb.2012.09.016  0.48
2012 Deenen MJ, Cats A, Mandigers CM, Soesan M, Terpstra WE, Beijnen JH, Schellens JH. [Prevention of severe toxicity from capecitabine, 5-fluorouracil and tegafur by screening for DPD-deficiency]. Nederlands Tijdschrift Voor Geneeskunde. 156: A4934. PMID 23191966  0.379
2012 Lankheet NA, Schaake EE, Rosing H, Burgers JA, Schellens JH, Beijnen JH, Huitema AD. Quantitative determination of erlotinib and O-desmethyl erlotinib in human EDTA plasma and lung tumor tissue. Bioanalysis. 4: 2563-77. PMID 23173792 DOI: 10.4155/Bio.12.235  0.42
2012 Moes J, Koolen S, Huitema A, Schellens J, Beijnen J, Nuijen B. Development of an oral solid dispersion formulation for use in low-dose metronomic chemotherapy of paclitaxel. European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V. 83: 87-94. PMID 23085332 DOI: 10.1016/j.ejpb.2012.09.016  0.393
2012 Dubbelman AC, Upthagrove A, Beijnen JH, Marchetti S, Tan E, Krone K, Anand S, Schellens JH. Disposition and metabolism of 14C-dovitinib (TKI258), an inhibitor of FGFR and VEGFR, after oral administration in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 70: 653-63. PMID 23010851 DOI: 10.1007/S00280-012-1947-2  0.5
2012 Sparidans RW, Tang SC, Nguyen LN, Schinkel AH, Schellens JH, Beijnen JH. Liquid chromatography-tandem mass spectrometric assay for the ALK inhibitor crizotinib in mouse plasma. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 905: 150-4. PMID 22940474 DOI: 10.1016/J.Jchromb.2012.08.021  0.474
2012 Ploquin A, Olmos D, Lacombe D, A'Hern R, Duhamel A, Twelves C, Marsoni S, Morales-Barrera R, Soria JC, Verweij J, Voest EE, Schöffski P, Schellens JH, Kramar A, Kristeleit RS, et al. Prediction of early death among patients enrolled in phase I trials: development and validation of a new model based on platelet count and albumin. British Journal of Cancer. 107: 1025-30. PMID 22910320 DOI: 10.1038/Bjc.2012.371  0.329
2012 Joerger M, Kraff S, Huitema AD, Feiss G, Moritz B, Schellens JH, Beijnen JH, Jaehde U. Evaluation of a pharmacology-driven dosing algorithm of 3-weekly paclitaxel using therapeutic drug monitoring: a pharmacokinetic-pharmacodynamic simulation study. Clinical Pharmacokinetics. 51: 607-17. PMID 22804749 DOI: 10.1007/Bf03261934  0.484
2012 Goey AK, Rosing H, Meijerman I, Sparidans RW, Schellens JH, Beijnen JH. The bioanalysis of the major Echinacea purpurea constituents dodeca-2E,4E,8Z,10E/Z-tetraenoic acid isobutylamides in human plasma using LC-MS/MS. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 902: 151-6. PMID 22770780 DOI: 10.1016/J.Jchromb.2012.06.022  0.446
2012 Leijen S, Middleton MR, Tresca P, Kraeber-Bodéré F, Dieras V, Scheulen ME, Gupta A, Lopez-Valverde V, Xu ZX, Rueger R, Tessier JJ, Shochat E, Blotner S, Naegelen VM, Schellens JH, et al. Phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of the MEK inhibitor RO4987655 (CH4987655) in patients with advanced solid tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 4794-805. PMID 22767668 DOI: 10.1158/1078-0432.Ccr-12-0868  0.337
2012 van Geel RM, Beijnen JH, Schellens JH. Concise drug review: pazopanib and axitinib. The Oncologist. 17: 1081-9. PMID 22733795 DOI: 10.1634/Theoncologist.2012-0055  0.457
2012 Keizer RJ, Zandvliet AS, Beijnen JH, Schellens JH, Huitema AD. Performance of methods for handling missing categorical covariate data in population pharmacokinetic analyses. The Aaps Journal. 14: 601-11. PMID 22648902 DOI: 10.1208/S12248-012-9373-2  0.376
2012 Boss DS, Glen H, Beijnen JH, Keesen M, Morrison R, Tait B, Copalu W, Mazur A, Wanders J, O'Brien JP, Schellens JH, Evans TR. A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours. British Journal of Cancer. 106: 1598-604. PMID 22516948 DOI: 10.1038/Bjc.2012.154  0.434
2012 Mooiman KD, Goey AK, Meijerman I, Beijnen JH, Schellens JH. Letter to the editor regarding "A prospective, controlled study of the botanical compound mixture LCS101 for chemotherapy-induced hematological complications in breast cancer" by Yaal-Hahoshen et al. (The Oncologist 2011;16:1197-1202). The Oncologist. 17: 740-1; author reply . PMID 22511266 DOI: 10.1634/Theoncologist.2011-0413  0.465
2012 Dubbelman AC, Jansen RS, Rosing H, Darwish M, Hellriegel E, Robertson P, Schellens JH, Beijnen JH. Metabolite profiling of bendamustine in urine of cancer patients after administration of [14C]bendamustine. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 40: 1297-307. PMID 22492615 DOI: 10.1124/Dmd.112.045229  0.442
2012 Opdam FL, Guchelaar HJ, Beijnen JH, Schellens JH. Lapatinib for advanced or metastatic breast cancer. The Oncologist. 17: 536-42. PMID 22477724 DOI: 10.1634/Theoncologist.2011-0461  0.411
2012 Sparidans RW, Durmus S, Xu N, Schinkel AH, Schellens JH, Beijnen JH. Liquid chromatography-tandem mass spectrometric assay for the VEGFR inhibitor cediranib and its primary human metabolite cediranib-N⁺-glucuronide in plasma. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 169-73. PMID 22476055 DOI: 10.1016/J.Jchromb.2012.03.020  0.481
2012 Sparidans RW, Durmus S, Xu N, Schinkel AH, Schellens JH, Beijnen JH. Liquid chromatography-tandem mass spectrometric assay for the JAK2 inhibitor CYT387 in plasma. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 174-7. PMID 22476054 DOI: 10.1016/J.Jchromb.2012.03.021  0.471
2012 Dubbelman AC, Tibben M, Rosing H, Gebretensae A, Nan L, Gorman SH, Robertson P, Schellens JH, Beijnen JH. Development and validation of LC-MS/MS assays for the quantification of bendamustine and its metabolites in human plasma and urine. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 893: 92-100. PMID 22426286 DOI: 10.1016/J.Jchromb.2012.02.039  0.481
2012 Jager NG, Rosing H, Linn SC, Schellens JH, Beijnen JH. Importance of highly selective LC-MS/MS analysis for the accurate quantification of tamoxifen and its metabolites: focus on endoxifen and 4-hydroxytamoxifen. Breast Cancer Research and Treatment. 133: 793-8. PMID 22388692 DOI: 10.1007/S10549-012-2000-1  0.435
2012 Sparidans RW, Durmus S, Schinkel AH, Schellens JH, Beijnen JH. Liquid chromatography-tandem mass spectrometric assay for the mutated BRAF inhibitor vemurafenib in human and mouse plasma. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 144-7. PMID 22386128 DOI: 10.1016/J.Jchromb.2012.02.010  0.475
2012 Jansen RS, Rosing H, Wijermans PW, Keizer RJ, Schellens JH, Beijnen JH. Decitabine triphosphate levels in peripheral blood mononuclear cells from patients receiving prolonged low-dose decitabine administration: a pilot study. Cancer Chemotherapy and Pharmacology. 69: 1457-66. PMID 22382880 DOI: 10.1007/S00280-012-1850-X  0.419
2012 Keizer RJ, Gupta A, Shumaker R, Beijnen JH, Schellens JH, Huitema AD. Model-based treatment optimization of a novel VEGFR inhibitor. British Journal of Clinical Pharmacology. 74: 315-26. PMID 22295876 DOI: 10.1111/J.1365-2125.2012.04197.X  0.458
2012 Vermaat JS, Gerritse FL, Van Der Veldt AA, Roessingh WM, Niers TM, Oosting SF, Sleijfer S, Roodhart JM, Beijnen JH, Schellens JH, Gietema JA, Boven E, Richel DJ, Haanen JB, Voest EE. Validation of serum amyloid α as an independent biomarker for progression-free and overall survival in metastatic renal cell cancer patients European Urology. 62: 685-696. PMID 22285764 DOI: 10.1016/J.Eururo.2012.01.020  0.35
2012 Dubbelman AC, Rosing H, Schellens JH, Beijnen JH. Bioanalytical aspects of clinical mass balance studies in oncology. Bioanalysis. 3: 2637-55. PMID 22136052 DOI: 10.4155/Bio.11.276  0.454
2012 Dubbelman AC, Rosing H, Jansen RS, Mergui-Roelvink M, Huitema AD, Koetz B, Lymboura M, Reyderman L, Lopez-Anaya A, Schellens JH, Beijnen JH. Mass balance study of [¹⁴C]eribulin in patients with advanced solid tumors. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 40: 313-21. PMID 22041109 DOI: 10.1124/Dmd.111.042762  0.495
2012 Joerger M, Burgers SA, Baas P, Smit EF, Haitjema TJ, Bard MP, Doodeman VD, Smits PH, Vincent A, Huitema AD, Beijnen JH, Schellens JH. Germline polymorphisms in patients with advanced nonsmall cell lung cancer receiving first-line platinum-gemcitabine chemotherapy: a prospective clinical study. Cancer. 118: 2466-75. PMID 22031394 DOI: 10.1002/Cncr.26562  0.425
2012 Joerger M, Ferreri AJ, Krähenbühl S, Schellens JH, Cerny T, Zucca E, Huitema AD. Dosing algorithm to target a predefined AUC in patients with primary central nervous system lymphoma receiving high dose methotrexate. British Journal of Clinical Pharmacology. 73: 240-7. PMID 21838788 DOI: 10.1111/J.1365-2125.2011.04084.X  0.339
2012 Keizer RJ, Zandvliet AS, Beijnen JH, Schellens JH, Huitema AD. Two-stage model-based design of cancer phase I dose escalation trials: evaluation using the phase I program of barasertib (AZD1152). Investigational New Drugs. 30: 1519-30. PMID 21626115 DOI: 10.1007/S10637-011-9694-5  0.452
2012 Joerger M, Burgers JA, Baas P, Doodeman VD, Smits PH, Jansen RS, Vainchtein LD, Rosing H, Huitema AD, Beijnen JH, Schellens JH. Gene polymorphisms, pharmacokinetics, and hematological toxicity in advanced non-small-cell lung cancer patients receiving cisplatin/gemcitabine. Cancer Chemotherapy and Pharmacology. 69: 25-33. PMID 21590444 DOI: 10.1007/S00280-011-1670-4  0.487
2012 Koolen SL, van Waterschoot RA, van Tellingen O, Schinkel AH, Beijnen JH, Schellens JH, Huitema AD. From mouse to man: predictions of human pharmacokinetics of orally administered docetaxel from preclinical studies. Journal of Clinical Pharmacology. 52: 370-80. PMID 21505085 DOI: 10.1177/0091270010397051  0.475
2012 Nannan Panday VR, van Warmerdam LJ, Huizing MT, Ten Bokkel Huinink WW, Vermorken JB, Giaccone G, Veenhof CH, Schellens JH, Beijnen JH. Carboplatin dosage formulae can generate inaccurate predictions of Carboplatin exposure in carboplatin/paclitaxel combination regimens. Clinical Drug Investigation. 15: 327-35. PMID 18370488 DOI: 10.2165/00044011-199815040-00009  0.444
2012 van Hasselt JC, van den Heuvel MM, Schellens JH, Beijnen JH, Brandsma D, Huitema A. Severe Cannabinoid Intoxication in A Patient with Non-Small-Cell Lung Cancer Journal of Palliative Care. 28: 60-61. DOI: 10.1177/082585971202800110  0.656
2011 Joerger M, Burgers SA, Baas P, Smit EF, Haitjema TJ, Bard MP, Doodeman VD, Smits PH, Vincent A, Huitema A, Beijnen JH, Schellens JH. Drug pathway-associated gene polymorphisms in patients with advanced non-small cell lung cancer receiving first-line platinum-gemcitabine combination chemotherapy: A prospective multicenter observational study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 7536. PMID 28023228 DOI: 10.1200/Jco.2011.29.15_Suppl.7536  0.339
2011 Schellens JH, Shapiro G, Pavlick AC, Tibes R, Leijen S, Tolaney SM, Diaz-Padilla I, Ramanathan RK, Demuth T, Viscusi J, Cheng JD, Lam R, Xu Y, Oza AM. Update on a phase I pharmacologic and pharmacodynamic study of MK-1775, a Wee1 tyrosine kinase inhibitor, in monotherapy and combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 3068. PMID 28022575 DOI: 10.1200/Jco.2011.29.15_Suppl.3068  0.304
2011 Devriese LA, Witteveen P, Voest EE, Overkleeft EN, Langenberg M, Beijnen JH, Reyderman L, Wanders J, Mould DR, Gupta A, Hussein Z, Schellens JH. Eribulin dosing in patients with advanced solid tumors and hepatic impairment. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 2544. PMID 28022319 DOI: 10.1200/jco.2011.29.15_suppl.2544  0.354
2011 Leijen S, Middleton MR, Tresca P, Kraeber-Bodere F, Dieras V, Scheulen ME, Tessier J, Xu ZX, Shochat E, Walz A, Deutsch J, Blotner S, Lopez Valverde V, Naegelen VM, Schellens JH, et al. Phase I (Ph) safety, pharmacodynamic (PD), and pharmacokinetic (PK) trial of a pure MEK inhibitor (i), RO4987655, in patients with advanced /metastatic solid tumor. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 3017. PMID 28022166 DOI: 10.1200/Jco.2011.29.15_Suppl.3017  0.319
2011 Bergamo A, Gaiddon C, Schellens JH, Beijnen JH, Sava G. Approaching tumour therapy beyond platinum drugs: status of the art and perspectives of ruthenium drug candidates. Journal of Inorganic Biochemistry. 106: 90-9. PMID 22112845 DOI: 10.1016/J.Jinorgbio.2011.09.030  0.444
2011 Lankheet NA, Blank CU, Mallo H, Adriaansz S, Rosing H, Schellens JH, Huitema AD, Beijnen JH. Determination of sunitinib and its active metabolite N-desethylsunitinib in sweat of a patient. Journal of Analytical Toxicology. 35: 558-65. PMID 22004675 DOI: 10.1093/Anatox/35.8.558  0.476
2011 Leijen S, Soetekouw PM, Jeffry Evans TR, Nicolson M, Schellens JH, Learoyd M, Grinsted L, Zazulina V, Pwint T, Middleton M. A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 68: 1619-28. PMID 21953275 DOI: 10.1007/S00280-011-1732-7  0.332
2011 Hendrikx JJ, Hillebrand MJ, Thijssen B, Rosing H, Schinkel AH, Schellens JH, Beijnen JH. A sensitive combined assay for the quantification of paclitaxel, docetaxel and ritonavir in human plasma using liquid chromatography coupled with tandem mass spectrometry. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 879: 2984-90. PMID 21920826 DOI: 10.1016/J.Jchromb.2011.08.034  0.486
2011 Gast MC, Zapatka M, van Tinteren H, Bontenbal M, Span PN, Tjan-Heijnen VC, Knol JC, Jimenez CR, Schellens JH, Beijnen JH. Postoperative serum proteomic profiles may predict recurrence-free survival in high-risk primary breast cancer. Journal of Cancer Research and Clinical Oncology. 137: 1773-83. PMID 21913038 DOI: 10.1007/S00432-011-1055-4  0.396
2011 Boekhout AH, Vincent AD, Dalesio OB, van den Bosch J, Foekema-Töns JH, Adriaansz S, Sprangers S, Nuijen B, Beijnen JH, Schellens JH. Management of hot flashes in patients who have breast cancer with venlafaxine and clonidine: a randomized, double-blind, placebo-controlled trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 3862-8. PMID 21911720 DOI: 10.1200/Jco.2010.33.1298  0.404
2011 Moes JJ, Koolen SL, Huitema AD, Schellens JH, Beijnen JH, Nuijen B. Pharmaceutical development and preliminary clinical testing of an oral solid dispersion formulation of docetaxel (ModraDoc001). International Journal of Pharmaceutics. 420: 244-50. PMID 21907780 DOI: 10.1016/J.Ijpharm.2011.08.041  0.469
2011 Caron WP, Clewell H, Dedrick R, Ramanathan RK, Davis WL, Yu N, Tonda M, Schellens JH, Beijnen JH, Zamboni WC. Allometric scaling of pegylated liposomal anticancer drugs. Journal of Pharmacokinetics and Pharmacodynamics. 38: 653-69. PMID 21863380 DOI: 10.1007/S10928-011-9213-5  0.346
2011 Deenen MJ, Klümpen HJ, Richel DJ, Sparidans RW, Weterman MJ, Beijnen JH, Schellens JH, Wilmink JW. Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies. Investigational New Drugs. 30: 1557-65. PMID 21809026 DOI: 10.1007/S10637-011-9723-4  0.449
2011 Koolen SL, Witteveen PO, Jansen RS, Langenberg MH, Kronemeijer RH, Nol A, Garcia-Ribas I, Callies S, Benhadji KA, Slapak CA, Beijnen JH, Voest EE, Schellens JH. Phase I study of Oral gemcitabine prodrug (LY2334737) alone and in combination with erlotinib in patients with advanced solid tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 6071-82. PMID 21753156 DOI: 10.1158/1078-0432.Ccr-11-0353  0.47
2011 Deenen MJ, Cats A, Beijnen JH, Schellens JH. Part 4: pharmacogenetic variability in anticancer pharmacodynamic drug effects. The Oncologist. 16: 1006-20. PMID 21659612 DOI: 10.1634/Theoncologist.2010-0261  0.443
2011 Deenen MJ, Cats A, Beijnen JH, Schellens JH. Part 3: Pharmacogenetic variability in phase II anticancer drug metabolism. The Oncologist. 16: 992-1005. PMID 21659608 DOI: 10.1634/Theoncologist.2010-0260  0.442
2011 Deenen MJ, Cats A, Beijnen JH, Schellens JH. Part 2: pharmacogenetic variability in drug transport and phase I anticancer drug metabolism. The Oncologist. 16: 820-34. PMID 21632461 DOI: 10.1634/Theoncologist.2010-0259  0.455
2011 Boekhout AH, Beijnen JH, Schellens JH. Trastuzumab. The Oncologist. 16: 800-10. PMID 21632460 DOI: 10.1634/theoncologist.2010-0035  0.338
2011 Deenen MJ, Cats A, Beijnen JH, Schellens JH. Part 1: background, methodology, and clinical adoption of pharmacogenetics. The Oncologist. 16: 811-9. PMID 21632456 DOI: 10.1634/theoncologist.2010-0258  0.38
2011 Sparidans RW, Martens I, Valkenburg-van Iersel LB, den Hartigh J, Schellens JH, Beijnen JH. Liquid chromatography-tandem mass spectrometric assay for the PARP-1 inhibitor olaparib in combination with the nitrogen mustard melphalan in human plasma. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 879: 1851-6. PMID 21622034 DOI: 10.1016/J.Jchromb.2011.05.003  0.5
2011 Devriese LA, Voest EE, Beijnen JH, Schellens JH. Circulating tumor cells as pharmacodynamic biomarker in early clinical oncological trials. Cancer Treatment Reviews. 37: 579-89. PMID 21592671 DOI: 10.1016/j.ctrv.2011.04.006  0.338
2011 Teunissen SF, Jager NG, Rosing H, Schinkel AH, Schellens JH, Beijnen JH. Development and validation of a quantitative assay for the determination of tamoxifen and its five main phase I metabolites in human serum using liquid chromatography coupled with tandem mass spectrometry. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 879: 1677-85. PMID 21543272 DOI: 10.1016/J.Jchromb.2011.04.011  0.471
2011 Joerger M, deJong D, Burylo A, Burgers JA, Baas P, Huitema AD, Beijnen JH, Schellens JH. Tubulin, BRCA1, ERCC1, Abraxas, RAP80 mRNA expression, p53/p21 immunohistochemistry and clinical outcome in patients with advanced non small-cell lung cancer receiving first-line platinum-gemcitabine chemotherapy. Lung Cancer (Amsterdam, Netherlands). 74: 310-7. PMID 21529986 DOI: 10.1016/J.Lungcan.2011.03.016  0.423
2011 Deenen MJ, Tol J, Burylo AM, Doodeman VD, de Boer A, Vincent A, Guchelaar HJ, Smits PH, Beijnen JH, Punt CJ, Schellens JH, Cats A. Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 3455-68. PMID 21498394 DOI: 10.1158/1078-0432.Ccr-10-2209  0.371
2011 Dubbelman AC, Rosing H, Thijssen B, Lucas L, Copalu W, Wanders J, Schellens JH, Beijnen JH. Validation of high-performance liquid chromatography-tandem mass spectrometry assays for the quantification of eribulin (E7389) in various biological matrices. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 879: 1149-55. PMID 21458392 DOI: 10.1016/J.Jchromb.2011.03.021  0.483
2011 Janssens T, Brouwers EE, de Vos JP, Schellens JH, Beijnen JH. Determination of platinum originating from carboplatin in human urine and canine excretion products by inductively coupled plasma mass spectrometry. Journal of Analytical Toxicology. 35: 153-61. PMID 21439151 DOI: 10.1093/Anatox/35.3.153  0.442
2011 Keizer RJ, Funahashi Y, Semba T, Wanders J, Beijnen JH, Schellens JH, Huitema AD. Evaluation of α2-integrin expression as a biomarker for tumor growth inhibition for the investigational integrin inhibitor E7820 in preclinical and clinical studies. The Aaps Journal. 13: 230-9. PMID 21387147 DOI: 10.1208/S12248-011-9260-2  0.34
2011 Keizer RJ, Schellens JH, Beijnen JH, Huitema AD. Pharmacodynamic biomarkers in model-based drug development in oncology. Current Clinical Pharmacology. 6: 30-40. PMID 21235464 DOI: 10.2174/157488411794941368  0.462
2011 Jänne PA, Boss DS, Camidge DR, Britten CD, Engelman JA, Garon EB, Guo F, Wong S, Liang J, Letrent S, Millham R, Taylor I, Eckhardt SG, Schellens JH. Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 1131-9. PMID 21220471 DOI: 10.1158/1078-0432.Ccr-10-1220  0.335
2011 van den Broek I, Sparidans RW, Engwegen JY, Cats A, Depla AC, Schellens JH, Beijnen JH. Evaluation of human neutrophil peptide-1, -2 and -3 as serum markers for colorectal cancer. Cancer Biomarkers : Section a of Disease Markers. 7: 109-15. PMID 21178269 DOI: 10.3233/Cbm-2010-0153  0.396
2011 van den Broek I, Sparidans RW, van Winden AW, Gast MC, van Dulken EJ, Schellens JH, Beijnen JH. The absolute quantification of eight inter-α-trypsin inhibitor heavy chain 4 (ITIH4)-derived peptides in serum from breast cancer patients. Proteomics. Clinical Applications. 4: 931-9. PMID 21137033 DOI: 10.1002/Prca.201000035  0.402
2011 Keizer RJ, van Benten M, Beijnen JH, Schellens JH, Huitema AD. Piraña and PCluster: a modeling environment and cluster infrastructure for NONMEM. Computer Methods and Programs in Biomedicine. 101: 72-9. PMID 20627442 DOI: 10.1016/J.Cmpb.2010.04.018  0.353
2011 Jansen RS, Rosing H, Schellens JH, Beijnen JH. Mass spectrometry in the quantitative analysis of therapeutic intracellular nucleotide analogs. Mass Spectrometry Reviews. 30: 321-43. PMID 20623700 DOI: 10.1002/Mas.20280  0.421
2011 Soto E, Keizer RJ, Trocóniz IF, Huitema AD, Beijnen JH, Schellens JH, Wanders J, Cendrós JM, Obach R, Peraire C, Friberg LE, Karlsson MO. Predictive ability of a semi-mechanistic model for neutropenia in the development of novel anti-cancer agents: two case studies. Investigational New Drugs. 29: 984-95. PMID 20449627 DOI: 10.1007/S10637-010-9437-Z  0.434
2011 Appels NM, Bolijn MJ, van Eijndhoven MA, Stephens TC, Beijnen JH, Schellens JH. Characterization of the in vitro activity of AZD3409, a novel prenyl transferase inhibitor. Cancer Chemotherapy and Pharmacology. 67: 137-45. PMID 20229082 DOI: 10.1007/S00280-010-1300-6  0.358
2011 Jansen RS, Rosing H, Schellens JH, Beijnen JH. Deoxyuridine analog nucleotides in deoxycytidine analog treatment: secondary active metabolites? Fundamental & Clinical Pharmacology. 25: 172-85. PMID 20199587 DOI: 10.1111/J.1472-8206.2010.00823.X  0.408
2011 Deenen MJ, Cats A, Beijnen JH, Schellens JH. Part 1: Background, Methodology, and Clinical Adoption of Pharmacogenetics The Oncologist. 16: 811-819. DOI: 10.1634/Theoncologist.2010-0258  0.465
2011 Boss DS, Glen H, Beijnen JH, de Jong D, Wanders J, Evans TJ, Schellens JH. Serum β-HCG and CA-125 as Tumor Markers in a Patient with Osteosarcoma: Case Report Tumori Journal. 97: 109-114. DOI: 10.1177/030089161109700119  0.389
2011 Devriese LA, Voest EE, Beijnen JH, Schellens JH. Circulating tumor cells as pharmacodynamic biomarker in early clinical oncological trials Cancer Treatment Reviews. 37: 579-589. DOI: 10.1016/J.Ctrv.2011.04.006  0.429
2010 Helgason HH, Engwegen JY, Zapatka M, Cats A, Boot H, Beijnen JH, Schellens JH. Serum proteomics and disease-specific biomarkers of patients with advanced gastric cancer. Oncology Letters. 1: 327-333. PMID 22966303 DOI: 10.3892/Ol_00000058  0.442
2010 Klümpen HJ, Beijnen JH, Gurney H, Schellens JH. Inhibitors of mTOR. The Oncologist. 15: 1262-9. PMID 21147869 DOI: 10.1634/Theoncologist.2010-0196  0.443
2010 van den Broek I, Sparidans RW, Schellens JH, Beijnen JH. Specific Investigation of Sample Handling Effects on Protease Activities and Absolute Serum Concentrations of Various Putative Peptidome Cancer Biomarkers. Clinical Proteomics. 6: 115-127. PMID 21124649 DOI: 10.1007/S12014-010-9054-Z  0.433
2010 Goey AK, Sparidans RW, Meijerman I, Rosing H, Schellens JH, Beijnen JH. A sensitive LC-MS/MS method for the quantitative analysis of the Echinacea purpurea constituent undeca-2-ene-8,10-diynoic acid isobutylamide in human plasma. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 879: 41-8. PMID 21123121 DOI: 10.1016/J.Jchromb.2010.11.007  0.459
2010 de Vries NA, Buckle T, Zhao J, Beijnen JH, Schellens JH, van Tellingen O. Restricted brain penetration of the tyrosine kinase inhibitor erlotinib due to the drug transporters P-gp and BCRP. Investigational New Drugs. 30: 443-9. PMID 20963470 DOI: 10.1007/S10637-010-9569-1  0.416
2010 Janssens T, Brouwers EE, de Vos JP, Schellens JH, Beijnen JH. Determination of platinum originating from carboplatin in canine sebum and cerumen by inductively coupled plasma mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis. 54: 395-400. PMID 20933356 DOI: 10.1016/J.Jpba.2010.09.014  0.439
2010 Sparidans RW, Iusuf D, Schinkel AH, Schellens JH, Beijnen JH. Liquid chromatography-tandem mass spectrometric assay for pravastatin and two isomeric metabolites in mouse plasma and tissue homogenates. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 878: 2751-9. PMID 20829130 DOI: 10.1016/J.Jchromb.2010.08.015  0.482
2010 Teunissen SF, Vlaming ML, Rosing H, Schellens JH, Schinkel AH, Beijnen JH. Development and validation of a liquid chromatography-tandem mass spectrometry assay for the analysis of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) and its metabolite 2-hydroxyamino-1-methyl-6-phenylimidazo[4,5-b]pyridine (N-OH-PhIP) in plasma, urine, bile, intestinal contents, faeces and eight selected tissues from mice. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 878: 2353-62. PMID 20708442 DOI: 10.1016/J.Jchromb.2010.07.012  0.452
2010 Keizer RJ, Gupta A, Mac Gillavry MR, Jansen M, Wanders J, Beijnen JH, Schellens JH, Karlsson MO, Huitema AD. A model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic drug E7080. Journal of Pharmacokinetics and Pharmacodynamics. 37: 347-63. PMID 20652729 DOI: 10.1007/S10928-010-9164-2  0.442
2010 Goey AK, Schellens JH, Beijnen JH, Huitema AD. [Dexrazoxane in anthracycline induced cardiotoxicity and extravasation]. Nederlands Tijdschrift Voor Geneeskunde. 154: A1155. PMID 20619024  0.3
2010 Keizer RJ, Huitema AD, Schellens JH, Beijnen JH. Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clinical Pharmacokinetics. 49: 493-507. PMID 20608753 DOI: 10.2165/11531280-000000000-00000  0.428
2010 Buikhuisen WA, Burgers JA, Vincent AD, Schellens JH, Beijnen JH, Smit EF, Joerger M. Pemetrexed pathway-associated germline polymorphisms: a useful tool for treatment individualization? Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: e482-3; author reply. PMID 20606096 DOI: 10.1200/Jco.2010.29.1559  0.419
2010 Sparidans RW, van Velsen SG, de Roos MP, Schellens JH, Bruijnzeel-Koomen CA, Beijnen JH. Liquid chromatography-tandem mass spectrometric assay for clobetasol propionate in human serum from patients with atopic dermatitis. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 878: 2150-4. PMID 20605116 DOI: 10.1016/J.Jchromb.2010.06.011  0.469
2010 Koolen SL, Oostendorp RL, Beijnen JH, Schellens JH, Huitema AD. Population pharmacokinetics of intravenously and orally administered docetaxel with or without co-administration of ritonavir in patients with advanced cancer. British Journal of Clinical Pharmacology. 69: 465-74. PMID 20573082 DOI: 10.1111/J.1365-2125.2010.03621.X  0.481
2010 van Winden AW, van den Broek I, Gast MC, Engwegen JY, Sparidans RW, van Dulken EJ, Depla AC, Cats A, Schellens JH, Peeters PH, Beijnen JH, van Gils CH. Serum degradome markers for the detection of breast cancer. Journal of Proteome Research. 9: 3781-8. PMID 20557135 DOI: 10.1021/Pr100395S  0.418
2010 Helgason HH, Engwegen JY, Zapatka M, Vincent A, Cats A, Boot H, Beijnen JH, Schellens JH. Identification of serum proteins as prognostic and predictive markers of colorectal cancer using surface enhanced laser desorption ionization-time of flight mass spectrometry. Oncology Reports. 24: 57-64. PMID 20514444 DOI: 10.3892/Or_00000828  0.437
2010 Gourley C, Michie CO, Roxburgh P, Yap TA, Harden S, Paul J, Ragupathy K, Todd R, Petty R, Reed N, Hayward RL, Mitchell P, Rye T, Schellens JH, Lubinski J, et al. Increased incidence of visceral metastases in scottish patients with BRCA1/2-defective ovarian cancer: an extension of the ovarian BRCAness phenotype. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 2505-11. PMID 20406939 DOI: 10.1200/Jco.2009.25.1082  0.305
2010 Fong PC, Yap TA, Boss DS, Carden CP, Mergui-Roelvink M, Gourley C, De Greve J, Lubinski J, Shanley S, Messiou C, A'Hern R, Tutt A, Ashworth A, Stone J, Carmichael J, ... Schellens JH, et al. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 2512-9. PMID 20406929 DOI: 10.1200/Jco.2009.26.9589  0.318
2010 Beijnen JH, Schellens JH. Personalized medicine in oncology: a personal view with myths and facts. Current Clinical Pharmacology. 5: 141-7. PMID 20406176 DOI: 10.2174/157488410791498789  0.404
2010 Leijen S, Beijnen JH, Schellens JH. Abrogation of the G2 checkpoint by inhibition of Wee-1 kinase results in sensitization of p53-deficient tumor cells to DNA-damaging agents. Current Clinical Pharmacology. 5: 186-91. PMID 20406171 DOI: 10.2174/157488410791498824  0.396
2010 Boss DS, Beijnen JH, Schellens JH. Inducing synthetic lethality using PARP inhibitors. Current Clinical Pharmacology. 5: 192-5. PMID 20406170 DOI: 10.2174/157488410791498798  0.419
2010 Jansen RS, Rosing H, Schellens JH, Beijnen JH. Facile small scale synthesis of nucleoside 5'-phosphate mixtures. Nucleosides, Nucleotides & Nucleic Acids. 29: 14-26. PMID 20391189 DOI: 10.1080/15257770903451546  0.383
2010 Oostendorp RL, Buckle T, Lambert G, Garrigue JS, Beijnen JH, Schellens JH, van Tellingen O. Paclitaxel in self-micro emulsifying formulations: oral bioavailability study in mice. Investigational New Drugs. 29: 768-76. PMID 20390333 DOI: 10.1007/S10637-010-9421-7  0.365
2010 van den Broek I, Sparidans RW, Schellens JH, Beijnen JH. Validation of a quantitative assay for human neutrophil peptide-1, -2, and -3 in human plasma and serum by liquid chromatography coupled to tandem mass spectrometry. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 878: 1085-92. PMID 20356805 DOI: 10.1016/J.Jchromb.2010.03.014  0.45
2010 Joerger M, Huitema AD, Krähenbühl S, Schellens JH, Cerny T, Reni M, Zucca E, Cavalli F, Ferreri AJ. Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: A pharmacokinetic-pharmacodynamic analysis from the IELSG no. 20 trial. British Journal of Cancer. 102: 673-7. PMID 20125159 DOI: 10.1038/Sj.Bjc.6605559  0.352
2010 Jansen RS, Rosing H, Kromdijk W, ter Heine R, Schellens JH, Beijnen JH. Simultaneous quantification of emtricitabine and tenofovir nucleotides in peripheral blood mononuclear cells using weak anion-exchange liquid chromatography coupled with tandem mass spectrometry. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 878: 621-7. PMID 20122883 DOI: 10.1016/J.Jchromb.2010.01.002  0.344
2010 van den Broek I, Sparidans RW, Schellens JH, Beijnen JH. Quantitative assay for six potential breast cancer biomarker peptides in human serum by liquid chromatography coupled to tandem mass spectrometry. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 878: 590-602. PMID 20116351 DOI: 10.1016/J.Jchromb.2010.01.011  0.443
2010 Vainchtein LD, Rosing H, Schellens JH, Beijnen JH. A new, validated HPLC-MS/MS method for the simultaneous determination of the anti-cancer agent capecitabine and its metabolites: 5'-deoxy-5-fluorocytidine, 5'-deoxy-5-fluorouridine, 5-fluorouracil and 5-fluorodihydrouracil, in human plasma. Biomedical Chromatography : Bmc. 24: 374-86. PMID 19650151 DOI: 10.1002/Bmc.1302  0.483
2010 Damen CW, Rosing H, Schellens JH, Beijnen JH. High-performance liquid chromatography coupled with mass spectrometry for the quantitative analysis of vinca-alkaloids in biological matrices: a concise survey from the literature. Biomedical Chromatography : Bmc. 24: 83-90. PMID 19606419 DOI: 10.1002/Bmc.1271  0.411
2010 Oostendorp RL, Witteveen PO, Schwartz B, Vainchtein LD, Schot M, Nol A, Rosing H, Beijnen JH, Voest EE, Schellens JH. Dose-finding and pharmacokinetic study of orally administered indibulin (D-24851) to patients with advanced solid tumors. Investigational New Drugs. 28: 163-70. PMID 19404582 DOI: 10.1007/S10637-009-9244-6  0.47
2010 Zandvliet AS, Karlsson MO, Schellens JH, Copalu W, Beijnen JH, Huitema AD. Two-stage model-based clinical trial design to optimize phase I development of novel anticancer agents. Investigational New Drugs. 28: 61-75. PMID 19198760 DOI: 10.1007/S10637-008-9216-2  0.45
2009 Harmsen S, Meijerman I, Febus CL, Maas-Bakker RF, Beijnen JH, Schellens JH. PXR-mediated induction of P-glycoprotein by anticancer drugs in a human colon adenocarcinoma-derived cell line. Cancer Chemotherapy and Pharmacology. 66: 765-71. PMID 20041327 DOI: 10.1007/S00280-009-1221-4  0.441
2009 Koolen SL, Beijnen JH, Schellens JH. Intravenous-to-oral switch in anticancer chemotherapy: a focus on docetaxel and paclitaxel. Clinical Pharmacology and Therapeutics. 87: 126-9. PMID 19924122 DOI: 10.1038/Clpt.2009.233  0.46
2009 Sparidans RW, Iusuf D, Schinkel AH, Schellens JH, Beijnen JH. Liquid chromatography-tandem mass spectrometric assay for the light sensitive tyrosine kinase inhibitor axitinib in human plasma. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 877: 4090-6. PMID 19910267 DOI: 10.1016/J.Jchromb.2009.10.024  0.468
2009 Gast MC, van Dulken EJ, van Loenen TK, Kingma-Vegter F, Westerga J, Flohil CC, Knol JC, Jimenez CR, van Gils CH, Wessels LF, Schellens JH, Beijnen JH. Detection of breast cancer by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry tissue and serum protein profiling. The International Journal of Biological Markers. 24: 130-41. PMID 19787623 DOI: 10.5301/Jbm.2009.3475  0.313
2009 Lankheet AG, Hillebrand MJ, Langenberg MH, Rosing H, Huitema AD, Voest EE, Schellens JH, Beijnen JH. A validated assay for the quantitative analysis of vatalanib in human EDTA plasma by liquid chromatography coupled with electrospray ionization tandem mass spectrometry. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 877: 3625-30. PMID 19762293 DOI: 10.1016/J.Jchromb.2009.09.001  0.486
2009 Pluim D, Beijnen JH, Schellens JH, van Tellingen O. Simultaneous determination of AZD1152 (prodrug) and AZD1152-hydroxyquinazoline pyrazol anilide by reversed phase liquid chromatography. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 877: 3549-55. PMID 19744901 DOI: 10.1016/J.Jchromb.2009.08.035  0.467
2009 Damen CW, Chen W, Chakraborty AB, van Oosterhout M, Mazzeo JR, Gebler JC, Schellens JH, Rosing H, Beijnen JH. Electrospray ionization quadrupole ion-mobility time-of-flight mass spectrometry as a tool to distinguish the lot-to-lot heterogeneity in N-glycosylation profile of the therapeutic monoclonal antibody trastuzumab. Journal of the American Society For Mass Spectrometry. 20: 2021-33. PMID 19744865 DOI: 10.1016/J.Jasms.2009.07.017  0.39
2009 Damen CW, Schellens JH, Beijnen JH. Bioanalytical methods for the quantification of therapeutic monoclonal antibodies and their application in clinical pharmacokinetic studies. Human Antibodies. 18: 47-73. PMID 19729801 DOI: 10.3233/Hab-2009-0206  0.433
2009 Koolen SL, Huitema AD, Jansen RS, van Voorthuizen T, Beijnen JH, Smit WM, Schellens JH. Pharmacokinetics of gemcitabine and metabolites in a patient with double-sided nephrectomy: a case report and review of the literature. The Oncologist. 14: 944-8. PMID 19726456 DOI: 10.1634/Theoncologist.2009-0111  0.484
2009 Jansen RS, Rosing H, Schellens JH, Beijnen JH. Simultaneous quantification of 2',2'-difluorodeoxycytidine and 2',2'-difluorodeoxyuridine nucleosides and nucleotides in white blood cells using porous graphitic carbon chromatography coupled with tandem mass spectrometry. Rapid Communications in Mass Spectrometry : Rcm. 23: 3040-50. PMID 19705384 DOI: 10.1002/Rcm.4212  0.433
2009 Jansen RS, Rosing H, Schellens JH, Beijnen JH. Protein versus DNA as a marker for peripheral blood mononuclear cell counting. Analytical and Bioanalytical Chemistry. 395: 863-7. PMID 19685233 DOI: 10.1007/S00216-009-3022-3  0.378
2009 Boss DS, Beijnen JH, Schellens JH. Clinical experience with aurora kinase inhibitors: a review. The Oncologist. 14: 780-93. PMID 19684075 DOI: 10.1634/Theoncologist.2009-0019  0.384
2009 Teunissen SF, Rosing H, Koornstra RH, Linn SC, Schellens JH, Schinkel AH, Beijnen JH. Development and validation of a quantitative assay for the analysis of tamoxifen with its four main metabolites and the flavonoids daidzein, genistein and glycitein in human serum using liquid chromatography coupled with tandem mass spectrometry. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 877: 2519-29. PMID 19589736 DOI: 10.1016/J.Jchromb.2009.06.029  0.493
2009 Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O'Connor MJ, Ashworth A, Carmichael J, Kaye SB, Schellens JH, de Bono JS. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. The New England Journal of Medicine. 361: 123-34. PMID 19553641 DOI: 10.1056/Nejmoa0900212  0.332
2009 Boss DS, Siegel-Lakhai WS, van Egmond-Schoemaker NE, Pluim D, Rosing H, Ten Bokkel Huinink WW, Beijnen JH, Schellens JH. Phase I pharmacokinetic and pharmacodynamic study of Carboplatin and topotecan administered intravenously every 28 days to patients with malignant solid tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 4475-83. PMID 19531625 DOI: 10.1158/1078-0432.Ccr-08-3144  0.461
2009 Damen CW, Speijer H, Hermens WT, Schellens JH, Rosing H, Beijnen JH. The bioanalysis of trastuzumab in human serum using precipitate-enhanced ellipsometry. Analytical Biochemistry. 393: 73-9. PMID 19523916 DOI: 10.1016/J.Ab.2009.06.006  0.416
2009 Gast MC, Van Gils CH, Wessels LF, Harris N, Bonfrer JM, Rutgers EJ, Schellens JH, Beijnen JH. Serum protein profiling for diagnosis of breast cancer using SELDI-TOF MS. Oncology Reports. 22: 205-13. PMID 19513525 DOI: 10.3892/Or_00000426  0.41
2009 Oostendorp RL, Huitema A, Rosing H, Jansen RS, Ter Heine R, Keessen M, Beijnen JH, Schellens JH. Coadministration of ritonavir strongly enhances the apparent oral bioavailability of docetaxel in patients with solid tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 4228-33. PMID 19509162 DOI: 10.1158/1078-0432.Ccr-08-2944  0.448
2009 Damen CW, Derissen EJ, Schellens JH, Rosing H, Beijnen JH. The bioanalysis of the monoclonal antibody trastuzumab by high-performance liquid chromatography with fluorescence detection after immuno-affinity purification from human serum. Journal of Pharmaceutical and Biomedical Analysis. 50: 861-6. PMID 19487098 DOI: 10.1016/J.Jpba.2009.04.031  0.411
2009 Damen CW, de Groot ER, Heij M, Boss DS, Schellens JH, Rosing H, Beijnen JH, Aarden LA. Development and validation of an enzyme-linked immunosorbent assay for the quantification of trastuzumab in human serum and plasma. Analytical Biochemistry. 391: 114-20. PMID 19464994 DOI: 10.1016/J.Ab.2009.05.030  0.434
2009 Gast MC, van Gils CH, Wessels LF, Harris N, Bonfrer JM, Rutgers EJ, Schellens JH, Beijnen JH. Influence of sample storage duration on serum protein profiles assessed by surface-enhanced laser desorption/ionisation time-of-flight mass spectrometry (SELDI-TOF MS). Clinical Chemistry and Laboratory Medicine : Cclm / Fescc. 47: 694-705. PMID 19416081 DOI: 10.1515/Cclm.2009.151  0.416
2009 Damen CW, Rosing H, Schellens JH, Beijnen JH. Application of dried blood spots combined with high-performance liquid chromatography coupled with electrospray ionisation tandem mass spectrometry for simultaneous quantification of vincristine and actinomycin-D. Analytical and Bioanalytical Chemistry. 394: 1171-82. PMID 19387621 DOI: 10.1007/S00216-009-2775-Z  0.434
2009 Brouwers EE, Huitema AD, Boogerd W, Beijnen JH, Schellens JH. Persistent neuropathy after treatment with cisplatin and oxaliplatin. Acta Oncologica (Stockholm, Sweden). 48: 832-41. PMID 19308757 DOI: 10.1080/02841860902806609  0.43
2009 Beumer JH, Franke NE, Tolboom R, Buckle T, Rosing H, Lopez-Lazaro L, Schellens JH, Beijnen JH, van Tellingen O. Disposition and toxicity of trabectedin (ET-743) in wild-type and mdr1 gene (P-gp) knock-out mice. Investigational New Drugs. 28: 145-55. PMID 19238326 DOI: 10.1007/S10637-009-9234-8  0.407
2009 Jansen RS, Rosing H, Schellens JH, Beijnen JH. Retention studies of 2'-2'-difluorodeoxycytidine and 2'-2'-difluorodeoxyuridine nucleosides and nucleotides on porous graphitic carbon: development of a liquid chromatography-tandem mass spectrometry method. Journal of Chromatography. A. 1216: 3168-74. PMID 19237159 DOI: 10.1016/J.Chroma.2009.02.002  0.385
2009 Damen CW, Israëls T, Caron HN, Schellens JH, Rosing H, Beijnen JH. Validated assay for the simultaneous quantification of total vincristine and actinomycin-D concentrations in human EDTA plasma and of vincristine concentrations in human plasma ultrafiltrate by high-performance liquid chromatography coupled with tandem mass spectrometry. Rapid Communications in Mass Spectrometry : Rcm. 23: 763-74. PMID 19204931 DOI: 10.1002/Rcm.3938  0.461
2009 Zandvliet AS, Schellens JH, Copalu W, Beijnen JH, Huitema AD. Covariate-based dose individualization of the cytotoxic drug indisulam to reduce the risk of severe myelosuppression. Journal of Pharmacokinetics and Pharmacodynamics. 36: 39-62. PMID 19199010 DOI: 10.1007/S10928-009-9111-2  0.46
2009 Beumer JH, Lopez-Lazaro L, Schellens JH, Beijnen JH, van Tellingen O. Evaluation of human plasma protein binding of trabectedin (Yondelis, ET-743). Current Clinical Pharmacology. 4: 38-42. PMID 19149499 DOI: 10.2174/157488409787236047  0.421
2009 Oostendorp RL, van de Steeg E, van der Kruijssen CM, Beijnen JH, Kenworthy KE, Schinkel AH, Schellens JH. Organic anion-transporting polypeptide 1B1 mediates transport of Gimatecan and BNP1350 and can be inhibited by several classic ATP-binding cassette (ABC) B1 and/or ABCG2 inhibitors. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 37: 917-23. PMID 19139163 DOI: 10.1124/Dmd.108.024901  0.419
2009 Brouwers EE, Söhne M, Kuipers S, van Gorp EC, Schellens JH, Koks CH, Beijnen JH, Huitema AD. Ciprofloxacin strongly inhibits clozapine metabolism: two case reports. Clinical Drug Investigation. 29: 59-63. PMID 19067475 DOI: 10.2165/0044011-200929010-00006  0.474
2009 Veltkamp SA, Witteveen EO, Capriati A, Crea A, Animati F, Voogel-Fuchs M, van den Heuvel IJ, Beijnen JH, Voest EE, Schellens JH. Clinical and pharmacologic study of the novel prodrug delimotecan (MEN 4901/T-0128) in patients with solid tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 7535-44. PMID 19010872 DOI: 10.1158/1078-0432.Ccr-08-0438  0.415
2009 Keizer RJ, Zamacona MK, Jansen M, Critchley D, Wanders J, Beijnen JH, Schellens JH, Huitema AD. Application of population pharmacokinetic modeling in early clinical development of the anticancer agent E7820. Investigational New Drugs. 27: 140-52. PMID 18712503 DOI: 10.1007/S10637-008-9164-X  0.461
2009 Vainchtein LD, Rosing H, Mirejovsky D, Huynh V, Lenaz L, Schellens JH, Beijnen JH. Simultaneous Quantitative Analysis of EO9 (Apaziquone) and its Conversion Products EO5a and EO9-Cl in Human and Dog Urine by High-Performance Liquid Chromatography Coupled with Electrospray Tandem Mass Spectrometry The Open Chemical and Biomedical Methods Journal. 2: 1-12. DOI: 10.2174/1875038900902010001  0.453
2008 Engwegen JY, Alberts M, Knol JC, Jimenez CR, Depla AC, Tuynman H, van Heukelem HA, Snel P, Smits ME, Cats A, Schellens JH, Beijnen JH. Influence of variations in sample handling on SELDI-TOF MS serum protein profiles for colorectal cancer. Proteomics. Clinical Applications. 2: 936-45. PMID 21136891 DOI: 10.1002/Prca.200780068  0.408
2008 Engwegen JY, Depla AC, Smits ME, Cats A, Tuynman H, van Heukelem HA, Snel P, Meuleman W, Wessels LF, Schellens JH, Beijnen JH. Detection of Colorectal Cancer by Serum and Tissue Protein Profiling: A Prospective Study in a Population at Risk. Biomarker Insights. 3: 375-385. PMID 19578519 DOI: 10.4137/Bmi.S790  0.412
2008 Sparidans RW, Vlaming ML, Lagas JS, Schinkel AH, Schellens JH, Beijnen JH. Liquid chromatography-tandem mass spectrometric assay for sorafenib and sorafenib-glucuronide in mouse plasma and liver homogenate and identification of the glucuronide metabolite. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 877: 269-76. PMID 19117812 DOI: 10.1016/J.Jchromb.2008.12.026  0.474
2008 Schellens JH, Beijnen JH. Novel clinical trial designs for innovative therapies. Clinical Pharmacology and Therapeutics. 85: 212-6. PMID 19109591 DOI: 10.1038/Clpt.2008.247  0.438
2008 Gast MC, Schellens JH, Beijnen JH. Clinical proteomics in breast cancer: a review. Breast Cancer Research and Treatment. 116: 17-29. PMID 19082706 DOI: 10.1007/S10549-008-0263-3  0.431
2008 Oostendorp RL, Beijnen JH, Schellens JH. The biological and clinical role of drug transporters at the intestinal barrier. Cancer Treatment Reviews. 35: 137-47. PMID 18986769 DOI: 10.1016/J.Ctrv.2008.09.004  0.438
2008 Harmsen S, Meijerman I, Beijnen JH, Schellens JH. Nuclear receptor mediated induction of cytochrome P450 3A4 by anticancer drugs: a key role for the pregnane X receptor. Cancer Chemotherapy and Pharmacology. 64: 35-43. PMID 18839173 DOI: 10.1007/S00280-008-0842-3  0.421
2008 Deenen MJ, Beijnen JH, Schellens JH. Is fluorouracil-induced severe toxicity in DPYD*2A individuals related to sex or to treatment regimen? Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 4997-8; author reply. PMID 18809598 DOI: 10.1200/Jco.2008.18.8565  0.417
2008 Brouwers EE, Huitema AD, Beijnen JH, Schellens JH. Long-term platinum retention after treatment with cisplatin and oxaliplatin. Bmc Clinical Pharmacology. 8: 7. PMID 18796166 DOI: 10.1186/1472-6904-8-7  0.457
2008 Huijbers EJ, Baars JW, Schutte PF, Schellens JH, Beijnen JH. Propofol extravasation in a breast cancer patient. Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners. 14: 195-8. PMID 18753182 DOI: 10.1177/1078155208094454  0.418
2008 van den Broek I, Sparidans RW, Schellens JH, Beijnen JH. Liquid chromatography/tandem mass spectrometric method for the quantification of eight proteolytic fragments of ITIH4 with biomarker potential in human plasma and serum. Rapid Communications in Mass Spectrometry : Rcm. 22: 2915-28. PMID 18752334 DOI: 10.1002/Rcm.3695  0.458
2008 Veltkamp SA, Pluim D, van Eijndhoven MA, Bolijn MJ, Ong FH, Govindarajan R, Unadkat JD, Beijnen JH, Schellens JH. New insights into the pharmacology and cytotoxicity of gemcitabine and 2',2'-difluorodeoxyuridine. Molecular Cancer Therapeutics. 7: 2415-25. PMID 18723487 DOI: 10.1158/1535-7163.Mct-08-0137  0.421
2008 Marchetti S, de Vries NA, Buckle T, Bolijn MJ, van Eijndhoven MA, Beijnen JH, Mazzanti R, van Tellingen O, Schellens JH. Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice. Molecular Cancer Therapeutics. 7: 2280-7. PMID 18723475 DOI: 10.1158/1535-7163.Mct-07-2250  0.429
2008 van den Broek I, Sparidans RW, Schellens JH, Beijnen JH. Quantitative bioanalysis of peptides by liquid chromatography coupled to (tandem) mass spectrometry. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 872: 1-22. PMID 18701357 DOI: 10.1016/J.Jchromb.2008.07.021  0.399
2008 Zandvliet AS, Schellens JH, Dittrich C, Wanders J, Beijnen JH, Huitema AD. Population pharmacokinetic and pharmacodynamic analysis to support treatment optimization of combination chemotherapy with indisulam and carboplatin. British Journal of Clinical Pharmacology. 66: 485-97. PMID 18637887 DOI: 10.1111/J.1365-2125.2008.03230.X  0.476
2008 Zandvliet AS, Schellens JH, Beijnen JH, Huitema AD. Population pharmacokinetics and pharmacodynamics for treatment optimization in clinical oncology. Clinical Pharmacokinetics. 47: 487-513. PMID 18611060 DOI: 10.2165/00003088-200847080-00001  0.475
2008 Brouwers EE, Huitema AD, Schellens JH, Beijnen JH. The effects of sulfur-containing compounds and gemcitabine on the binding of cisplatin to plasma proteins and DNA determined by inductively coupled plasma mass spectrometry and high performance liquid chromatography-inductively coupled plasma mass spectrometry. Anti-Cancer Drugs. 19: 621-30. PMID 18525322 DOI: 10.1097/Cad.0B013E3282Ffd6A4  0.389
2008 Veltkamp SA, Jansen RS, Callies S, Pluim D, Visseren-Grul CM, Rosing H, Kloeker-Rhoades S, Andre VA, Beijnen JH, Slapak CA, Schellens JH. Oral administration of gemcitabine in patients with refractory tumors: a clinical and pharmacologic study. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 3477-86. PMID 18519780 DOI: 10.1158/1078-0432.Ccr-07-4521  0.486
2008 Appels NM, Bolijn MJ, Chan K, Stephens TC, Hoctin-Boes G, Middleton M, Beijnen JH, de Bono JS, Harris AL, Schellens JH. Phase I pharmacokinetic and pharmacodynamic study of the prenyl transferase inhibitor AZD3409 in patients with advanced cancer. British Journal of Cancer. 98: 1951-8. PMID 18506143 DOI: 10.1038/Sj.Bjc.6604402  0.512
2008 Damen CW, Rosing H, Tibben MM, van Maanen MJ, Lagas JS, Schinkel AH, Schellens JH, Beijnen JH. A sensitive assay for the quantitative analysis of vinorelbine in mouse and human EDTA plasma by high-performance liquid chromatography coupled with electrospray tandem mass spectrometry. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 868: 102-9. PMID 18501686 DOI: 10.1016/J.Jchromb.2008.04.046  0.468
2008 Veltkamp SA, Pluim D, van Tellingen O, Beijnen JH, Schellens JH. Extensive metabolism and hepatic accumulation of gemcitabine after multiple oral and intravenous administration in mice. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 36: 1606-15. PMID 18490432 DOI: 10.1124/Dmd.108.021048  0.469
2008 Siegel-Lakhai WS, Zandvliet AS, Huitema AD, Tibben MM, Milano G, Girre V, Diéras V, King A, Richmond E, Wanders J, Beijnen JH, Schellens JH. A dose-escalation study of indisulam in combination with capecitabine (Xeloda) in patients with solid tumours. British Journal of Cancer. 98: 1320-6. PMID 18414469 DOI: 10.1038/Sj.Bjc.6604300  0.484
2008 Meijerman I, Beijnen JH, Schellens JH. Combined action and regulation of phase II enzymes and multidrug resistance proteins in multidrug resistance in cancer. Cancer Treatment Reviews. 34: 505-20. PMID 18413281 DOI: 10.1016/J.Ctrv.2008.03.002  0.415
2008 Brouwers EE, Tibben MM, Pluim D, Rosing H, Boot H, Cats A, Schellens JH, Beijnen JH. Inductively coupled plasma mass spectrometric analysis of the total amount of platinum in DNA extracts from peripheral blood mononuclear cells and tissue from patients treated with cisplatin. Analytical and Bioanalytical Chemistry. 391: 577-85. PMID 18385987 DOI: 10.1007/S00216-008-2034-8  0.43
2008 Harmsen S, Koster AS, Beijnen JH, Schellens JH, Meijerman I. Comparison of two immortalized human cell lines to study nuclear receptor-mediated CYP3A4 induction. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 36: 1166-71. PMID 18347084 DOI: 10.1124/Dmd.107.017335  0.406
2008 Boss DS, Olmos RV, Sinaasappel M, Beijnen JH, Schellens JH. Application of PET/CT in the development of novel anticancer drugs. The Oncologist. 13: 25-38. PMID 18245010 DOI: 10.1634/Theoncologist.2007-0097  0.367
2008 Vainchtein LD, Rosing H, Mirejovsky D, Huynh V, Lenaz L, Schellens JH, Beijnen JH. Enhanced resolution triple-quadrupole mass spectrometry for ultra-sensitive and quantitative analysis of the investigational anticancer agent EO9 (apaziquone) and its metabolite EO5a in human and dog plasma to support (pre)-clinical studies of EOquin given intravesically. Rapid Communications in Mass Spectrometry : Rcm. 22: 462-70. PMID 18231986 DOI: 10.1002/Rcm.3387  0.473
2007 Damen CW, Rosing H, Schellens JH, Beijnen JH. Quantitative aspects of the analysis of the monoclonal antibody trastuzumab using high-performance liquid chromatography coupled with electrospray mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis. 46: 449-55. PMID 18096347 DOI: 10.1016/J.Jpba.2007.11.002  0.413
2007 Marchetti S, Oostendorp RL, Pluim D, van Eijndhoven M, van Tellingen O, Schinkel AH, Versace R, Beijnen JH, Mazzanti R, Schellens JH. In vitro transport of gimatecan (7-t-butoxyiminomethylcamptothecin) by breast cancer resistance protein, P-glycoprotein, and multidrug resistance protein 2. Molecular Cancer Therapeutics. 6: 3307-13. PMID 18089724 DOI: 10.1158/1535-7163.Mct-07-0461  0.325
2007 Joerger M, Huitema AD, Richel DJ, Dittrich C, Pavlidis N, Briasoulis E, Vermorken JB, Strocchi E, Martoni A, Sorio R, Sleeboom HP, Izquierdo MA, Jodrell DI, Féty R, de Bruijn E, ... ... Schellens JH, et al. Population pharmacokinetics and pharmacodynamics of doxorubicin and cyclophosphamide in breast cancer patients: a study by the EORTC-PAMM-NDDG. Clinical Pharmacokinetics. 46: 1051-68. PMID 18027989 DOI: 10.2165/00003088-200746120-00005  0.495
2007 Joerger M, Huitema AD, Richel DJ, Dittrich C, Pavlidis N, Briasoulis E, Vermorken JB, Strocchi E, Martoni A, Sorio R, Sleeboom HP, Izquierdo MA, Jodrell DI, Calvert H, Boddy AV, ... ... Schellens JH, et al. Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: a study by the European organization for research and treatment of cancer-pharmacology and molecular mechanisms group and new drug development group. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 6410-8. PMID 17975154 DOI: 10.1158/1078-0432.Ccr-07-0064  0.461
2007 Joerger M, Huitema AD, Huizing MT, Willemse PH, de Graeff A, Rosing H, Schellens JH, Beijnen JH, Vermorken JB. Safety and pharmacology of paclitaxel in patients with impaired liver function: a population pharmacokinetic-pharmacodynamic study. British Journal of Clinical Pharmacology. 64: 622-33. PMID 17935602 DOI: 10.1111/J.1365-2125.2007.02956.X  0.454
2007 Zandvliet AS, Siegel-Lakhai WS, Beijnen JH, Copalu W, Etienne-Grimaldi MC, Milano G, Schellens JH, Huitema AD. PK/PD model of indisulam and capecitabine: interaction causes excessive myelosuppression. Clinical Pharmacology and Therapeutics. 83: 829-39. PMID 17851564 DOI: 10.1038/Sj.Clpt.6100344  0.467
2007 Marchetti S, Mazzanti R, Beijnen JH, Schellens JH. Concise review: Clinical relevance of drug drug and herb drug interactions mediated by the ABC transporter ABCB1 (MDR1, P-glycoprotein). The Oncologist. 12: 927-41. PMID 17766652 DOI: 10.1634/Theoncologist.12-8-927  0.445
2007 Marchetti S, Schellens JH. The impact of FDA and EMEA guidelines on drug development in relation to Phase 0 trials. British Journal of Cancer. 97: 577-81. PMID 17726450 DOI: 10.1038/Sj.Bjc.6603925  0.358
2007 Siegel-Lakhai WS, Beijnen JH, Vervenne WL, Boot H, Keessen M, Versola M, Koch KM, Smith DA, Pandite L, Richel DJ, Schellens JH. Phase I pharmacokinetic study of the safety and tolerability of lapatinib (GW572016) in combination with oxaliplatin/fluorouracil/leucovorin (FOLFOX4) in patients with solid tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 4495-502. PMID 17671135 DOI: 10.1158/1078-0432.Ccr-07-0004  0.448
2007 Rademaker-Lakhai JM, Beerepoot LV, Mehra N, Radema SA, van Maanen R, Vermaat JS, Witteveen EO, Visseren-Grul CM, Musib L, Enas N, van Hal G, Beijnen JH, Schellens JH, Voest EE. Phase I pharmacokinetic and pharmacodynamic study of the oral protein kinase C beta-inhibitor enzastaurin in combination with gemcitabine and cisplatin in patients with advanced cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 4474-81. PMID 17671132 DOI: 10.1158/1078-0432.CCR-06-2912  0.33
2007 Vainchtein LD, Rosing H, Maier A, Fiebig HH, Schellens JH, Beijnen JH. Quantitative and selective assay of 5-methylindirubine, an inhibitor of cyclin-dependent kinases, in murine plasma using coupled liquid chromatography and electrospray tandem mass spectrometry. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 856: 261-6. PMID 17631060 DOI: 10.1016/J.Jchromb.2007.06.006  0.461
2007 Bröker LE, Veltkamp SA, Heath EI, Kuenen BC, Gall H, Astier L, Parker S, Kayitalire L, Lorusso PM, Schellens JH, Giaccone G. A phase I safety and pharmacologic study of a twice weekly dosing regimen of the oral taxane BMS-275183. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 3906-12. PMID 17606724 DOI: 10.1158/1078-0432.Ccr-06-2875  0.34
2007 Vainchtein LD, Rosing H, Thijssen B, Schellens JH, Beijnen JH. Validated assay for the simultaneous determination of the anti-cancer agent gemcitabine and its metabolite 2',2'-difluorodeoxyuridine in human plasma by high-performance liquid chromatography with tandem mass spectrometry. Rapid Communications in Mass Spectrometry : Rcm. 21: 2312-22. PMID 17577879 DOI: 10.1002/Rcm.3096  0.472
2007 Kuppens IE, Witteveen EO, Jewell RC, Radema SA, Paul EM, Mangum SG, Beijnen JH, Voest EE, Schellens JH. A phase I, randomized, open-label, parallel-cohort, dose-finding study of elacridar (GF120918) and oral topotecan in cancer patients. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 3276-85. PMID 17545533 DOI: 10.1158/1078-0432.Ccr-06-2414  0.481
2007 Zandvliet AS, Huitema AD, Copalu W, Yamada Y, Tamura T, Beijnen JH, Schellens JH. CYP2C9 and CYP2C19 polymorphic forms are related to increased indisulam exposure and higher risk of severe hematologic toxicity. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 2970-6. PMID 17504998 DOI: 10.1158/1078-0432.Ccr-06-2978  0.422
2007 van den Broek I, Sparidans RW, Schellens JH, Beijnen JH. Enzymatic digestion as a tool for the LC-MS/MS quantification of large peptides in biological matrices: measurement of chymotryptic fragments from the HIV-1 fusion inhibitor enfuvirtide and its metabolite M-20 in human plasma. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 854: 245-59. PMID 17500050 DOI: 10.1016/J.Jchromb.2007.04.026  0.443
2007 Harmsen S, Meijerman I, Beijnen JH, Schellens JH. The role of nuclear receptors in pharmacokinetic drug-drug interactions in oncology. Cancer Treatment Reviews. 33: 369-80. PMID 17451886 DOI: 10.1016/J.Ctrv.2007.02.003  0.459
2007 Brouwers EE, Tibben MM, Rosing H, Schellens JH, Beijnen JH. Determination of ruthenium originating from the investigational anti-cancer drug NAMI-A in human plasma ultrafiltrate, plasma, and urine by inductively coupled plasma mass spectrometry. Rapid Communications in Mass Spectrometry : Rcm. 21: 1521-30. PMID 17410551 DOI: 10.1002/Rcm.2985  0.479
2007 Bosch TM, Bakker R, Schellens JH, Cats A, Smits PH, Beijnen JH. Rapid detection of the DPYD IVS14+1G>A mutation for screening patients to prevent fluorouracil-related toxicity. Molecular Diagnosis & Therapy. 11: 105-8. PMID 17397246 DOI: 10.1007/Bf03256229  0.371
2007 Oostendorp RL, Beijnen JH, Schellens JH, Tellingen Ov. Determination of imatinib mesylate and its main metabolite (CGP74588) in human plasma and murine specimens by ion-pairing reversed-phase high-performance liquid chromatography. Biomedical Chromatography : Bmc. 21: 747-54. PMID 17385801 DOI: 10.1002/Bmc.816  0.474
2007 Brouwers EE, Huitema AD, Bakker EN, Douma JW, Schimmel KJ, van Weringh G, de Wolf PJ, Schellens JH, Beijnen JH. Monitoring of platinum surface contamination in seven Dutch hospital pharmacies using inductively coupled plasma mass spectrometry. International Archives of Occupational and Environmental Health. 80: 689-99. PMID 17377802 DOI: 10.1007/S00420-007-0181-4  0.408
2007 Meijerman I, Sanderson LM, Smits PH, Beijnen JH, Schellens JH. Pharmacogenetic screening of the gene deletion and duplications of CYP2D6. Drug Metabolism Reviews. 39: 45-60. PMID 17364880 DOI: 10.1080/03602530600952206  0.408
2007 Beumer JH, Garner RC, Cohen MB, Galbraith S, Duncan GF, Griffin T, Beijnen JH, Schellens JH. Human mass balance study of the novel anticancer agent ixabepilone using accelerator mass spectrometry. Investigational New Drugs. 25: 327-34. PMID 17347871 DOI: 10.1007/S10637-007-9041-Z  0.519
2007 Sparidans RW, Prins JM, Schellens JH, Beijnen JH. Liquid chromatography-tandem mass spectrometric assay for the nucleoside reverse transcriptase inhibitor emtricitabine in human plasma. Biomedical Chromatography : Bmc. 21: 621-7. PMID 17340566 DOI: 10.1002/bmc.797  0.398
2007 Engwegen JY, Mehra N, Haanen JB, Bonfrer JM, Schellens JH, Voest EE, Beijnen JH. Validation of SELDI-TOF MS serum protein profiles for renal cell carcinoma in new populations. Laboratory Investigation; a Journal of Technical Methods and Pathology. 87: 161-72. PMID 17318195 DOI: 10.1038/Labinvest.3700503  0.426
2007 Campone M, Rademaker-Lakhai JM, Bennouna J, Howell SB, Nowotnik DP, Beijnen JH, Schellens JH. Phase I and pharmacokinetic trial of AP5346, a DACH-platinum-polymer conjugate, administered weekly for three out of every 4 weeks to advanced solid tumor patients. Cancer Chemotherapy and Pharmacology. 60: 523-33. PMID 17308894 DOI: 10.1007/S00280-006-0397-0  0.441
2007 Vink SR, van Blitterswijk WJ, Schellens JH, Verheij M. Rationale and clinical application of alkylphospholipid analogues in combination with radiotherapy. Cancer Treatment Reviews. 33: 191-202. PMID 17287087 DOI: 10.1016/J.Ctrv.2006.12.001  0.334
2007 Gast MC, Bonfrer JM, van Dulken EJ, de Kock L, Rutgers EJ, Schellens JH, Beijnen JH. SELDI-TOF MS serum protein profiles in breast cancer: assessment of robustness and validity. Cancer Biomarkers : Section a of Disease Markers. 2: 235-48. PMID 17264395 DOI: 10.3233/Cbm-2006-2602  0.408
2007 Veltkamp SA, Rosing H, Huitema AD, Fetell MR, Nol A, Beijnen JH, Schellens JH. Novel paclitaxel formulations for oral application: a phase I pharmacokinetic study in patients with solid tumours. Cancer Chemotherapy and Pharmacology. 60: 635-42. PMID 17205304 DOI: 10.1007/S00280-006-0405-4  0.476
2007 Oostendorp RL, Marchetti S, Beijnen JH, Mazzanti R, Schellens JH. The effect of hydroxyurea on P-glycoprotein/BCRP-mediated transport and CYP3A metabolism of imatinib mesylate. Cancer Chemotherapy and Pharmacology. 59: 855-60. PMID 17180388 DOI: 10.1007/S00280-006-0334-2  0.418
2007 Breedveld P, Pluim D, Cipriani G, Dahlhaus F, van Eijndhoven MA, de Wolf CJ, Kuil A, Beijnen JH, Scheffer GL, Jansen G, Borst P, Schellens JH. The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models. Molecular Pharmacology. 71: 240-9. PMID 17032904 DOI: 10.1124/Mol.106.028167  0.365
2007 Vainchtein LD, Rosing H, Mirejovsky D, Lenaz L, Schellens JH, Beijnen JH. Stability experiments in human urine with EO9 (apaziquone): a novel anticancer agent for the intravesical treatment of bladder cancer. Journal of Pharmaceutical and Biomedical Analysis. 43: 285-92. PMID 16920321 DOI: 10.1016/J.Jpba.2006.06.044  0.45
2007 Brandon EF, Sparidans RW, van Ooijen RD, Meijerman I, Lazaro LL, Manzanares I, Beijnen JH, Schellens JH. In vitro characterization of the human biotransformation pathways of aplidine, a novel marine anti-cancer drug. Investigational New Drugs. 25: 9-19. PMID 16633717 DOI: 10.1007/S10637-006-7589-7  0.453
2007 Beumer JH, Buckle T, Ouwehand M, Franke NE, Lopez-Lazaro L, Schellens JH, Beijnen JH, van Tellingen O. Trabectedin (ET-743, Yondelis) is a substrate for P-glycoprotein, but only high expression of P-glycoprotein confers the multidrug resistance phenotype. Investigational New Drugs. 25: 1-7. PMID 16633714 DOI: 10.1007/S10637-006-7773-9  0.406
2007 Appels NM, Rosing H, Stephens TC, Schellens JH, Beijnen JH. Quantification of farnesylmethylcysteine in lysates of peripheral blood mononuclear cells using liquid chromatography coupled with electrospray tandem mass spectrometry: pharmacodynamic assay for farnesyl transferase inhibitors. Analytical Chemistry. 78: 2617-22. PMID 16615771 DOI: 10.1021/Ac051786S  0.477
2007 Rademaker-Lakhai JM, Beerepoot LV, Mehra N, Radema SA, van Maanen R, Vermaat JS, Witteveen EO, Visseren-Grul CM, Musib L, Enas N, van Hal G, Beijnen JH, Schellens JH, Voest EE. Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Protein Kinase C  -Inhibitor Enzastaurin in Combination with Gemcitabine and Cisplatin in Patients with Advanced Cancer Clinical Cancer Research. 13: 4474-4481. DOI: 10.1158/1078-0432.Ccr-06-2912  0.478
2007 Sparidans RW, Prins JM, Schellens JH, Beijnen JH. Liquid chromatography–tandem mass spectrometric assay for the nucleoside reverse transcriptase inhibitor emtricitabine in human plasma Biomedical Chromatography. 21: 621-627. DOI: 10.1002/Bmc.797  0.481
2006 Kuppens IE, Witteveen PO, Schot M, Schuessler VM, Daehling A, Beijnen JH, Voest EE, Schellens JH. Phase I dose-finding and pharmacokinetic trial of orally administered indibulin (D-24851) to patients with solid tumors. Investigational New Drugs. 25: 227-35. PMID 17146730 DOI: 10.1007/S10637-006-9027-2  0.467
2006 Bosch TM, Huitema AD, Doodeman VD, Jansen R, Witteveen E, Smit WM, Jansen RL, van Herpen CM, Soesan M, Beijnen JH, Schellens JH. Pharmacogenetic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of docetaxel. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 5786-93. PMID 17020985 DOI: 10.1158/1078-0432.Ccr-05-2649  0.457
2006 Siegel-Lakhai WS, Crul M, De Porre P, Zhang S, Chang I, Boot H, Beijnen JH, Schellens JH. Clinical and pharmacologic study of the farnesyltransferase inhibitor tipifarnib in cancer patients with normal or mildly or moderately impaired hepatic function. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 4558-64. PMID 17008695 DOI: 10.1200/Jco.2006.05.8123  0.441
2006 Beumer JH, Rademaker-Lakhai JM, Rosing H, Hillebrand MJ, Bosch TM, Lopez-Lazaro L, Schellens JH, Beijnen JH. Metabolism of trabectedin (ET-743, Yondelis) in patients with advanced cancer. Cancer Chemotherapy and Pharmacology. 59: 825-37. PMID 16988825 DOI: 10.1007/s00280-006-0342-2  0.372
2006 Vainchtein LD, Rosing H, Mirejovsky D, Huynh V, Lenaz L, Hillebrand MJ, Schellens JH, Beijnen JH. Quantitative analysis of EO9 (apaziquone) and its metabolite EO5a in human plasma by high-performance liquid chromatography under basic conditions coupled to electrospray tandem mass spectrometry. Journal of Mass Spectrometry : Jms. 41: 1268-76. PMID 16981212 DOI: 10.1002/Jms.1086  0.468
2006 Helgason HH, Kruijtzer CM, Huitema AD, Marcus SG, ten Bokkel Huinink WW, Schot ME, Schornagel JH, Beijnen JH, Schellens JH. Phase II and pharmacological study of oral paclitaxel (Paxoral) plus ciclosporin in anthracycline-pretreated metastatic breast cancer. British Journal of Cancer. 95: 794-800. PMID 16969354 DOI: 10.1038/Sj.Bjc.6603332  0.49
2006 Zandvliet AS, Schellens JH, Copalu W, Beijnen JH, Huitema AD. A semi-physiological population pharmacokinetic model describing the non-linear disposition of indisulam. Journal of Pharmacokinetics and Pharmacodynamics. 33: 543-70. PMID 16946998 DOI: 10.1007/S10928-006-9021-5  0.456
2006 Brouwers EE, Tibben MM, Rosing H, Hillebrand MJ, Joerger M, Schellens JH, Beijnen JH. Sensitive inductively coupled plasma mass spectrometry assay for the determination of platinum originating from cisplatin, carboplatin, and oxaliplatin in human plasma ultrafiltrate. Journal of Mass Spectrometry : Jms. 41: 1186-94. PMID 16929560 DOI: 10.1002/Jms.1087  0.474
2006 Veltkamp SA, Thijssen B, Garrigue JS, Lambert G, Lallemand F, Binlich F, Huitema AD, Nuijen B, Nol A, Beijnen JH, Schellens JH. A novel self-microemulsifying formulation of paclitaxel for oral administration to patients with advanced cancer. British Journal of Cancer. 95: 729-34. PMID 16926835 DOI: 10.1038/Sj.Bjc.6603312  0.475
2006 Joerger M, Huitema AD, Boogerd W, van der Sande JJ, Schellens JH, Beijnen JH. Interactions of serum albumin, valproic acid and carbamazepine with the pharmacokinetics of phenytoin in cancer patients. Basic & Clinical Pharmacology & Toxicology. 99: 133-40. PMID 16918714 DOI: 10.1111/J.1742-7843.2006.Pto_309.X  0.482
2006 Vink SR, Schellens JH, Beijnen JH, Sindermann H, Engel J, Dubbelman R, Moppi G, Hillebrand MJ, Bartelink H, Verheij M. Phase I and pharmacokinetic study of combined treatment with perifosine and radiation in patients with advanced solid tumours. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. 80: 207-13. PMID 16914220 DOI: 10.1016/J.Radonc.2006.07.032  0.441
2006 Meijerman I, Beijnen JH, Schellens JH. Herb-drug interactions in oncology: focus on mechanisms of induction. The Oncologist. 11: 742-52. PMID 16880233 DOI: 10.1634/Theoncologist.11-7-742  0.458
2006 Joerger M, Huitema AD, van den Bongard HJ, Baas P, Schornagel JH, Schellens JH, Beijnen JH. Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients. British Journal of Clinical Pharmacology. 62: 71-80. PMID 16842380 DOI: 10.1111/J.1365-2125.2005.02513.X  0.445
2006 Sparidans RW, Dost F, Crommentuyn KM, Huitema AD, Schellens JH, Beijnen JH. Liquid chromatographic assay for the non-peptidic protease inhibitor tipranavir in plasma. Biomedical Chromatography : Bmc. 20: 671-3. PMID 16799929 DOI: 10.1002/Bmc.667  0.458
2006 Joerger M, Bosch TM, Doodeman VD, Beijnen JH, Smits PH, Schellens JH. Novel deoxycytidine kinase gene polymorphisms: a population screening study in Caucasian healthy volunteers. European Journal of Clinical Pharmacology. 62: 681-4. PMID 16799820 DOI: 10.1007/S00228-006-0162-7  0.388
2006 Boekhout AH, Beijnen JH, Schellens JH. Symptoms and treatment in cancer therapy-induced early menopause. The Oncologist. 11: 641-54. PMID 16794243 DOI: 10.1634/Theoncologist.11-6-641  0.406
2006 van den Berg JH, Beijnen JH, Balm AJ, Schellens JH. Future opportunities in preventing cisplatin induced ototoxicity. Cancer Treatment Reviews. 32: 390-7. PMID 16781082 DOI: 10.1016/J.Ctrv.2006.04.011  0.411
2006 Kuppens IE, Dansin E, Boot H, Feger C, Assadourian S, Bonneterre ME, Beijnen JH, Schellens JH, Bonneterre J. Dose-finding phase I clinical and pharmacokinetic study of orally administered irinotecan in patients with advanced solid tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 3774-81. PMID 16778105 DOI: 10.1158/1078-0432.Ccr-05-2368  0.474
2006 Bosch TM, Doodeman VD, Smits PH, Meijerman I, Schellens JH, Beijnen JH. Pharmacogenetic screening for polymorphisms in drug-metabolizing enzymes and drug transporters in a Dutch population. Molecular Diagnosis & Therapy. 10: 175-85. PMID 16771603 DOI: 10.1007/Bf03256456  0.429
2006 van den Broek I, Sparidans RW, Huitema AD, Schellens JH, Beijnen JH. Development and validation of a quantitative assay for the measurement of two HIV-fusion inhibitors, enfuvirtide and tifuvirtide, and one metabolite of enfuvirtide (M-20) in human plasma by liquid chromatography-tandem mass spectrometry. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 837: 49-58. PMID 16713406 DOI: 10.1016/J.Jchromb.2006.03.059  0.467
2006 Veltkamp SA, Alderden-Los C, Sharma A, Rosing H, Beijnen JH, Schellens JH. A pharmacokinetic and safety study of a novel polymeric paclitaxel formulation for oral application. Cancer Chemotherapy and Pharmacology. 59: 43-50. PMID 16680462 DOI: 10.1007/S00280-006-0245-2  0.431
2006 Vlaming ML, Mohrmann K, Wagenaar E, de Waart DR, Elferink RP, Lagas JS, van Tellingen O, Vainchtein LD, Rosing H, Beijnen JH, Schellens JH, Schinkel AH. Carcinogen and anticancer drug transport by Mrp2 in vivo: studies using Mrp2 (Abcc2) knockout mice. The Journal of Pharmacology and Experimental Therapeutics. 318: 319-27. PMID 16611851 DOI: 10.1124/Jpet.106.101774  0.439
2006 Joerger M, Huitema AD, van den Bongard DH, Schellens JH, Beijnen JH. Quantitative effect of gender, age, liver function, and body size on the population pharmacokinetics of Paclitaxel in patients with solid tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 2150-7. PMID 16609028 DOI: 10.1158/1078-0432.Ccr-05-2069  0.472
2006 Engwegen JY, Gast MC, Schellens JH, Beijnen JH. Clinical proteomics: searching for better tumour markers with SELDI-TOF mass spectrometry. Trends in Pharmacological Sciences. 27: 251-9. PMID 16600386 DOI: 10.1016/J.Tips.2006.03.003  0.41
2006 Engwegen JY, Helgason HH, Cats A, Harris N, Bonfrer JM, Schellens JH, Beijnen JH. Identification of serum proteins discriminating colorectal cancer patients and healthy controls using surface-enhanced laser desorption ionisation-time of flight mass spectrometry. World Journal of Gastroenterology. 12: 1536-44. PMID 16570345 DOI: 10.3748/wjg.v12.i10.1536  0.302
2006 Bosch TM, Deenen M, Pruntel R, Smits PH, Schellens JH, Beijnen JH, Meijerman I. Screening for polymorphisms in the PXR gene in a Dutch population. European Journal of Clinical Pharmacology. 62: 395-9. PMID 16568343 DOI: 10.1007/S00228-006-0108-0  0.375
2006 Zandvliet AS, Copalu W, Schellens JH, Beijnen JH, Huitema AD. Saturable binding of indisulam to plasma proteins and distribution to human erythrocytes. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 34: 1041-6. PMID 16565173 DOI: 10.1124/Dmd.105.008326  0.414
2006 Appels NM, Rosing H, Stephens TC, Hughes A, Schellens JH, Beijnen JH. Absolute quantification of farnesylated Ras levels in complex samples using liquid chromatography fractionation combined with tryptic digestion and electrospray tandem mass spectrometry. Analytical Biochemistry. 352: 33-40. PMID 16564488 DOI: 10.1016/J.Ab.2006.02.028  0.418
2006 Vink SR, Lagerwerf S, Mesman E, Schellens JH, Begg AC, van Blitterswijk WJ, Verheij M. Radiosensitization of squamous cell carcinoma by the alkylphospholipid perifosine in cell culture and xenografts. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 1615-22. PMID 16533789 DOI: 10.1158/1078-0432.Ccr-05-2033  0.305
2006 Sparidans RW, Bosch TM, Jörger M, Schellens JH, Beijnen JH. Liquid chromatography-tandem mass spectrometric assay for the analysis of uracil, 5,6-dihydrouracil and beta-ureidopropionic acid in urine for the measurement of the activities of the pyrimidine catabolic enzymes. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 839: 45-53. PMID 16513432 DOI: 10.1016/J.Jchromb.2006.02.016  0.461
2006 Bosch TM, Meijerman I, Beijnen JH, Schellens JH. Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer. Clinical Pharmacokinetics. 45: 253-85. PMID 16509759 DOI: 10.2165/00003088-200645030-00003  0.469
2006 Rademaker-Lakhai JM, Crul M, Zuur L, Baas P, Beijnen JH, Simis YJ, van Zandwijk N, Schellens JH. Relationship between cisplatin administration and the development of ototoxicity. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 918-24. PMID 16484702 DOI: 10.1200/JCO.2006.10.077  0.337
2006 Beumer JH, Beijnen JH, Schellens JH. Mass balance studies, with a focus on anticancer drugs. Clinical Pharmacokinetics. 45: 33-58. PMID 16430310 DOI: 10.2165/00003088-200645010-00003  0.491
2006 Brandon EF, Sparidans RW, Guijt KJ, Löwenthal S, Meijerman I, Beijnen JH, Schellens JH. In vitro characterization of the human biotransformation and CYP reaction phenotype of ET-743 (Yondelis, Trabectidin), a novel marine anti-cancer drug. Investigational New Drugs. 24: 3-14. PMID 16379042 DOI: 10.1007/S10637-005-4538-9  0.425
2006 Siegel-Lakhai WS, Beijnen JH, Schellens JH. Current knowledge and future directions of the selective epidermal growth factor receptor inhibitors erlotinib (Tarceva) and gefitinib (Iressa). The Oncologist. 10: 579-89. PMID 16177282 DOI: 10.1634/Theoncologist.10-8-579  0.401
2006 Appels NM, Beijnen JH, Schellens JH. Development of farnesyl transferase inhibitors: a review. The Oncologist. 10: 565-78. PMID 16177281 DOI: 10.1634/Theoncologist.10-8-565  0.427
2006 Vainchtein LD, Thijssen B, Stokvis E, Rosing H, Schellens JH, Beijnen JH. A simple and sensitive assay for the quantitative analysis of paclitaxel and metabolites in human plasma using liquid chromatography/tandem mass spectrometry. Biomedical Chromatography : Bmc. 20: 139-48. PMID 16041788 DOI: 10.1002/Bmc.544  0.476
2006 Appels NM, Tung KO, Rosing H, Schellens JH, Beijnen JH. A rapid and simple HPLC-UV method for the determination of inhibition characteristics of farnesyl transferase inhibitors. Biomedical Chromatography : Bmc. 20: 161-5. PMID 16032760 DOI: 10.1002/Bmc.545  0.407
2006 Brandon EF, Bosch TM, Deenen MJ, Levink R, van der Wal E, van Meerveld JB, Bijl M, Beijnen JH, Schellens JH, Meijerman I. Validation of in vitro cell models used in drug metabolism and transport studies; genotyping of cytochrome P450, phase II enzymes and drug transporter polymorphisms in the human hepatoma (HepG2), ovarian carcinoma (IGROV-1) and colon carcinoma (CaCo-2, LS180) cell lines. Toxicology and Applied Pharmacology. 211: 1-10. PMID 15975613 DOI: 10.1016/J.Taap.2005.05.004  0.424
2006 Sparidans RW, Dost F, Crommentuyn KM, Huitema AD, Schellens JH, Beijnen JH. Liquid chromatographic assay for the protease inhibitor atazanavir in plasma. Biomedical Chromatography : Bmc. 20: 72-6. PMID 15954163 DOI: 10.1002/Bmc.530  0.48
2006 Bosch TM, Kjellberg LM, Bouwers A, Koeleman BP, Schellens JH, Beijnen JH, Smits PH, Meijerman I. Detection of single nucleotide polymorphisms in the ABCG2 gene in a Dutch population. American Journal of Pharmacogenomics : Genomics-Related Research in Drug Development and Clinical Practice. 5: 123-31. PMID 15813675 DOI: 10.2165/00129785-200505020-00005  0.43
2006 Bosch T, Meijerman I, Beijnen J, Schellens J. Genetic Polymorphisms of Drug Metabolising Enzymes and Drug Transporters in Relation to Cancer Risk Current Cancer Therapy Reviews. 2: 137-155. DOI: 10.2174/157339406776872825  0.415
2006 Beerepoot L, Rademaker-Lakhai J, Witteveen E, Radema S, Viseren-Grul C, Musib L, Van Hal J, Beijnen J, Schellens J, Voest E. Phase I and pharmacokinetic evaluation of enzastaurin combined with gemcitabine and cisplatin in advanced cancer Journal of Clinical Oncology. 24: 2046-2046. DOI: 10.1200/jco.2006.24.18_suppl.2046  0.37
2006 Rademaker-Lakhai JM, Crul M, Zuur L, Baas P, Beijnen JH, Simis YJ, van Zandwijk N, Schellens JH. Relationship Between Cisplatin Administration and the Development of Ototoxicity Journal of Clinical Oncology. 24: 918-924. DOI: 10.1200/Jco.2006.10.077  0.449
2005 Breedveld P, Beijnen JH, Schellens JH. Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs. Trends in Pharmacological Sciences. 27: 17-24. PMID 16337012 DOI: 10.1016/J.Tips.2005.11.009  0.462
2005 Siegel-Lakhai WS, Crul M, Zhang S, Sparidans RW, Pluim D, Howes A, Solanki B, Beijnen JH, Schellens JH. Phase I and pharmacological study of the farnesyltransferase inhibitor tipifarnib (Zarnestra, R115777) in combination with gemcitabine and cisplatin in patients with advanced solid tumours. British Journal of Cancer. 93: 1222-9. PMID 16251868 DOI: 10.1038/Sj.Bjc.6602850  0.481
2005 Kuppens IE, Breedveld P, Beijnen JH, Schellens JH. Modulation of oral drug bioavailability: from preclinical mechanism to therapeutic application. Cancer Investigation. 23: 443-64. PMID 16193644 DOI: 10.1081/Cnv-58823  0.45
2005 Rademaker-Lakhai JM, Crul M, Pluim D, Sparidans RW, Baas P, Beijnen JH, van Zandwijk N, Schellens JH. Phase I clinical and pharmacologic study of a 2-weekly administration of cisplatin and gemcitabine in patients with advanced non-small cell lung cancer. Anti-Cancer Drugs. 16: 1029-36. PMID 16162981 DOI: 10.1097/01.Cad.0000176507.78928.4D  0.479
2005 Brandon EF, Meijerman I, Klijn JS, den Arend D, Sparidans RW, Lázaro LL, Beijnen JH, Schellens JH. In-vitro cytotoxicity of ET-743 (Trabectedin, Yondelis), a marine anti-cancer drug, in the Hep G2 cell line: influence of cytochrome P450 and phase II inhibition, and cytochrome P450 induction. Anti-Cancer Drugs. 16: 935-43. PMID 16162970 DOI: 10.1097/01.Cad.0000180121.16407.38  0.44
2005 Beumer JH, Hillebrand MJ, Pluim D, Rosing H, Foley K, Yule SM, Schellens JH, Beijnen JH. Human metabolism of [(14)C]indisulam following i.v. infusion in cancer patients. Investigational New Drugs. 23: 317-30. PMID 16012791 DOI: 10.1007/S10637-005-1440-4  0.48
2005 Vink SR, Schellens JH, van Blitterswijk WJ, Verheij M. Tumor and normal tissue pharmacokinetics of perifosine, an oral anti-cancer alkylphospholipid. Investigational New Drugs. 23: 279-86. PMID 16012787 DOI: 10.1007/S10637-005-1436-0  0.374
2005 Appels NM, van Maanen MJ, Rosing H, Schellens JH, Beijnen JH. Quantitative analysis of the farnesyl transferase inhibitor lonafarnib (Sarasartrade mark, SCH66336) in human plasma using high-performance liquid chromatography coupled with tandem mass spectrometry. Rapid Communications in Mass Spectrometry : Rcm. 19: 2187-92. PMID 15996016 DOI: 10.1002/Rcm.2046  0.49
2005 Brouwers EE, Tibben MM, Joerger M, van Tellingen O, Rosing H, Schellens JH, Beijnen JH. Determination of oxaliplatin in human plasma and plasma ultrafiltrate by graphite-furnace atomic-absorption spectrometry. Analytical and Bioanalytical Chemistry. 382: 1484-90. PMID 15952001 DOI: 10.1007/S00216-005-3302-5  0.451
2005 Kappelhoff BS, Huitema AD, Mairuhu AT, Schellens JH, Beijnen JH. No pharmacokinetic drug-drug interaction between nevirapine and paclitaxel. Anti-Cancer Drugs. 16: 627-30. PMID 15930890 DOI: 10.1097/00001813-200507000-00006  0.493
2005 Brandon EF, van Ooijen RD, Sparidans RW, Lázaro LL, Heck AJ, Beijnen JH, Schellens JH. Structure elucidation of aplidine metabolites formed in vitro by human liver microsomes using triple quadrupole mass spectrometry. Journal of Mass Spectrometry : Jms. 40: 821-31. PMID 15892174 DOI: 10.1002/Jms.863  0.428
2005 van Kesteren C, Zandvliet AS, Karlsson MO, Mathôt RA, Punt CJ, Armand JP, Raymond E, Huitema AD, Dittrich C, Dumez H, Roché HH, Droz JP, Ravic M, Yule SM, Wanders J, ... ... Schellens JH, et al. Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulam. Investigational New Drugs. 23: 225-34. PMID 15868378 DOI: 10.1007/S10637-005-6730-3  0.714
2005 Bardelmeijer HA, Roelofs AB, Hillebrand MJ, Beijnen JH, Schellens JH, van Tellingen O. Metabolism of docetaxel in mice. Cancer Chemotherapy and Pharmacology. 56: 299-306. PMID 15864592 DOI: 10.1007/S00280-004-0945-4  0.413
2005 van Herwaarden AE, Smit JW, Sparidans RW, Wagenaar E, van der Kruijssen CM, Schellens JH, Beijnen JH, Schinkel AH. Midazolam and cyclosporin a metabolism in transgenic mice with liver-specific expression of human CYP3A4. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 33: 892-5. PMID 15845749 DOI: 10.1124/Dmd.105.004721  0.444
2005 de Maat MM, Beijnen JH, Schellens JH, Mulder JW. Chronic hepatotoxicity after long-term antiretroviral treatment including nevirapine. The Journal of Infection. 50: 262-4. PMID 15780424 DOI: 10.1016/J.Jinf.2004.02.011  0.443
2005 Rademaker-Lakhai JM, Horenblas S, Meinhardt W, Stokvis E, de Reijke TM, Jimeno JM, Lopez-Lazaro L, Lopez Martin JA, Beijnen JH, Schellens JH. Phase I clinical and pharmacokinetic study of kahalalide F in patients with advanced androgen refractory prostate cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 1854-62. PMID 15756010 DOI: 10.1158/1078-0432.Ccr-04-1534  0.436
2005 Beumer JH, Schellens JH, Beijnen JH. Hepatotoxicity and metabolism of trabectedin: a literature review. Pharmacological Research. 51: 391-8. PMID 15749453 DOI: 10.1016/J.Phrs.2004.12.001  0.431
2005 Joerger M, Huitema AD, Meenhorst PL, Schellens JH, Beijnen JH. Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma. Cancer Chemotherapy and Pharmacology. 55: 488-96. PMID 15726371 DOI: 10.1007/S00280-004-0900-4  0.481
2005 van Tellingen O, Bardelmeijer HA, Buckle T, Ouwehand M, Beijnen JH, Schellens JH. Cannulation of the jugular vein in mice. Laboratory Animals. 39: 130. PMID 15703135 DOI: 10.1258/0023677052886466  0.326
2005 Schoemaker NE, Kuppens IE, Huinink WW, Lefebvre P, Beijnen JH, Assadourian S, Sanderink GJ, Schellens JH. Phase I study of an oral formulation of irinotecan administered daily for 14 days every 3 weeks in patients with advanced solid tumours. Cancer Chemotherapy and Pharmacology. 55: 263-70. PMID 15592838 DOI: 10.1007/S00280-004-0874-2  0.483
2005 Kuppens IE, van Maanen MJ, Rosing H, Schellens JH, Beijnen JH. Quantitative analysis of docetaxel in human plasma using liquid chromatography coupled with tandem mass spectrometry. Biomedical Chromatography : Bmc. 19: 355-61. PMID 15586372 DOI: 10.1002/Bmc.457  0.465
2005 Stokvis E, Rosing H, López-Lázaro L, Schellens JH, Beijnen JH. A more sensitive MS detector does not obviously lead to a more sensitive assay: experiences with ES-285. Biomedical Chromatography : Bmc. 18: 403-7. PMID 15273982 DOI: 10.1002/Bmc.404  0.476
2004 Lakhai WS, Beijnen JH, Den Boer SS, Westermann AM, Versola M, Koch K, Ho P, Pandite L, Richel DJ, Schellens J. Phase I trial to determine the safety and tolerability of GW572016 in combination with oxaliplatin (OX)/5-fluorouracil (5-FU)/leucovorin (LV) [FOLFOX4] in patients with solid tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 2044. PMID 28015625 DOI: 10.1200/Jco.2004.22.14_Suppl.2044  0.443
2004 Joerger M, Schellens JH, Beijnen JH. Therapeutic drug monitoring of non-anticancer drugs in cancer patients. Methods and Findings in Experimental and Clinical Pharmacology. 26: 531-45. PMID 15538543 DOI: 10.1358/Mf.2004.26.7.863736  0.485
2004 Fracasso PM, Goldstein LJ, de Alwis DP, Rader JS, Arquette MA, Goodner SA, Wright LP, Fears CL, Gazak RJ, Andre VA, Burgess MF, Slapak CA, Schellens JH. Phase I study of docetaxel in combination with the P-glycoprotein inhibitor, zosuquidar, in resistant malignancies. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 7220-8. PMID 15534095 DOI: 10.1158/1078-0432.Ccr-04-0452  0.367
2004 Beumer JH, Rosing H, Hillebrand MJ, Nan-Offeringa LG, Foley K, Yule SM, Heck AJ, Schellens JH, Beijnen JH. Quantitative determination of the novel anticancer drug E7070 (indisulam) and its metabolite (1,4-benzenedisulphonamide) in human plasma, urine and faeces by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry. Rapid Communications in Mass Spectrometry : Rcm. 18: 2839-48. PMID 15517526 DOI: 10.1002/Rcm.1699  0.49
2004 Stokvis E, Rosing H, Causon RC, Schellens JH, Beijnen JH. Quantitative analysis of the P-glycoprotein inhibitor Elacridar (GF120918) in human and dog plasma using liquid chromatography with tandem mass spectrometric detection. Journal of Mass Spectrometry : Jms. 39: 1122-30. PMID 15468145 DOI: 10.1002/Jms.687  0.471
2004 Schoemaker NE, Kuppens IE, Moiseyenko V, Glimelius B, Kjaer M, Starkhammer H, Richel DJ, Smaaland R, Bertelsen K, Poulsen JP, Voznyi E, Norum J, Fennelly D, Tveit KM, Garin A, ... ... Schellens JH, et al. A randomised phase II multicentre trial of irinotecan (CPT-11) using four different schedules in patients with metastatic colorectal cancer. British Journal of Cancer. 91: 1434-41. PMID 15381932 DOI: 10.1038/Sj.Bjc.6602172  0.448
2004 Kuppens IE, Beijnen J, Schellens JH. Topoisomerase I inhibitors in the treatment of gastrointestinal cancer: from intravenous to oral administration. Clinical Colorectal Cancer. 4: 163-80. PMID 15377400 DOI: 10.3816/ccc.2004.n.017  0.394
2004 Kuppens IE, Bosch TM, van Maanen MJ, Rosing H, Fitzpatrick A, Beijnen JH, Schellens JH. Oral bioavailability of docetaxel in combination with OC144-093 (ONT-093). Cancer Chemotherapy and Pharmacology. 55: 72-8. PMID 15316750 DOI: 10.1007/S00280-004-0864-4  0.429
2004 Breedveld P, Zelcer N, Pluim D, Sönmezer O, Tibben MM, Beijnen JH, Schinkel AH, van Tellingen O, Borst P, Schellens JH. Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions. Cancer Research. 64: 5804-11. PMID 15313923 DOI: 10.1158/0008-5472.Can-03-4062  0.425
2004 Beijnen JH, Schellens JH. Drug interactions in oncology. The Lancet. Oncology. 5: 489-96. PMID 15288238 DOI: 10.1016/S1470-2045(04)01528-1  0.439
2004 Peters GJ, Noordhuis P, Van Groeningen CJ, Giaccone G, Holwerda U, Voorn D, Schrijvers A, Schornagel JH, Beijnen JH, Fumoleau P, Schellens JH. The effect of food on the pharmacokinetics of S-1 after single oral administration to patients with solid tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 4072-6. PMID 15217941 DOI: 10.1158/1078-0432.Ccr-1076-03  0.422
2004 Stokvis E, Nan-Offeringa LG, Ouwehand M, Tibben MM, Rosing H, Schnaars Y, Grigat M, Romeis P, Schellens JH, Beijnen JH. Quantitative analysis of D-24851, a novel anticancer agent, in human plasma and urine by liquid chromatography coupled with tandem mass spectrometry. Rapid Communications in Mass Spectrometry : Rcm. 18: 1465-71. PMID 15216507 DOI: 10.1002/Rcm.1493  0.465
2004 Rademaker-Lakhai JM, van den Bongard D, Pluim D, Beijnen JH, Schellens JH. A Phase I and pharmacological study with imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a novel ruthenium anticancer agent. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 3717-27. PMID 15173078 DOI: 10.1158/1078-0432.Ccr-03-0746  0.466
2004 Rademaker-Lakhai JM, Terret C, Howell SB, Baud CM, De Boer RF, Pluim D, Beijnen JH, Schellens JH, Droz JP. A Phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 3386-95. PMID 15161693 DOI: 10.1158/1078-0432.Ccr-03-0315  0.427
2004 Kerbusch T, Groenewegen G, Mathôt RA, Herben VM, ten Bokkel Huinink WW, Swart M, Ambaum B, Rosing H, Jansen S, Voest EE, Beijnen JH, Schellens JH. Phase I and pharmacokinetic study of the combination of topotecan and ifosfamide administered intravenously every 3 weeks. British Journal of Cancer. 90: 2268-77. PMID 15150579 DOI: 10.1038/Sj.Bjc.6601861  0.443
2004 Brandon EF, Sparidans RW, Meijerman I, Manzanares I, Beijnen JH, Schellens JH. In vitro characterization of the biotransformation of thiocoraline, a novel marine anti-cancer drug. Investigational New Drugs. 22: 241-51. PMID 15122071 DOI: 10.1023/B:Drug.0000026250.34645.7F  0.451
2004 Bardelmeijer HA, Ouwehand M, Beijnen JH, Schellens JH, van Tellingen O. Efficacy of novel P-glycoprotein inhibitors to increase the oral uptake of paclitaxel in mice. Investigational New Drugs. 22: 219-29. PMID 15122069 DOI: 10.1023/B:Drug.0000026248.45084.21  0.443
2004 Crommentuyn KM, Mulder JW, Sparidans RW, Huitema AD, Schellens JH, Beijnen JH. Drug-drug interaction between itraconazole and the antiretroviral drug lopinavir/ritonavir in an HIV-1-infected patient with disseminated histoplasmosis. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 38: e73-5. PMID 15095234 DOI: 10.1086/382675  0.436
2004 de Jonge ME, van den Bongard HJ, Huitema AD, Mathôt RA, Rosing H, Baas P, van Zandwijk N, Beijnen JH, Schellens JH. Bayesian pharmacokinetically guided dosing of paclitaxel in patients with non-small cell lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 2237-44. PMID 15073098 DOI: 10.1158/1078-0432.Ccr-03-0060  0.717
2004 Stokvis E, Rosing H, Crul M, Rieser MJ, Heck AJ, Schellens JH, Beijnen JH. Quantitative analysis of the novel anticancer drug ABT-518, a matrix metalloproteinase inhibitor, plus the screening of six metabolites in human plasma using high-performance liquid chromatography coupled with electrospray tandem mass spectrometry. Journal of Mass Spectrometry : Jms. 39: 277-88. PMID 15039935 DOI: 10.1002/Jms.579  0.506
2004 Pluim D, van Waardenburg RC, Beijnen JH, Schellens JH. Cytotoxicity of the organic ruthenium anticancer drug Nami-A is correlated with DNA binding in four different human tumor cell lines. Cancer Chemotherapy and Pharmacology. 54: 71-8. PMID 15034754 DOI: 10.1007/S00280-004-0773-6  0.39
2004 Kuppens IE, Boot H, Beijnen JH, Schellens JH, Labadie J. Capecitabine induces severe angina-like chest pain. Annals of Internal Medicine. 140: 494-5. PMID 15023730 DOI: 10.7326/0003-4819-140-6-200403160-00034  0.322
2004 Sparidans RW, Schellens JH, López-Lázaro L, Jimeno JM, Beijnen JH. Liquid chromatographic assay for the cyclic depsipeptide aplidine, a new marine antitumor drug, in whole blood using derivatization with trans-4'-hydrazino-2-stilbazole. Biomedical Chromatography : Bmc. 18: 16-20. PMID 14872544 DOI: 10.1002/Bmc.286  0.451
2004 van den Bongard HJ, Kemper EM, van Tellingen O, Rosing H, Mathôt RA, Schellens JH, Beijnen JH. Development and validation of a method to determine the unbound paclitaxel fraction in human plasma. Analytical Biochemistry. 324: 11-5. PMID 14654039 DOI: 10.1016/J.Ab.2003.07.024  0.621
2004 Crul M, Schoemaker NE, Pluim D, Maliepaard M, Underberg RW, Schot M, Sparidans RW, Baas P, Beijnen JH, Van Zandwijk N, Schellens JH. Randomized phase I clinical and pharmacologic study of weekly versus twice-weekly dose-intensive cisplatin and gemcitabine in patients with advanced non-small cell lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 9: 3526-33. PMID 14506138  0.349
2004 Sparidans RW, Crommentuyn KM, Schellens JH, Beijnen JH. Liquid chromatographic assay for the antiviral nucleotide analogue tenofovir in plasma using derivatization with chloroacetaldehyde. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 791: 227-33. PMID 12798182 DOI: 10.1016/S1570-0232(03)00225-3  0.456
2004 Kuppens IE, Beijnen JH, Schellens JH. Topoisomerase I Inhibitors in the Treatment of Gastrointestinal Cancer: From Intravenous to Oral Administration Clinical Colorectal Cancer. 4: 163-180. DOI: 10.3816/Ccc.2004.N.017  0.477
2004 Gast M, Bonfrer J, Rutgers E, Schellens J, Beijnen J. New discriminatory serum protein profiles in breast cancer patients Journal of Clinical Oncology. 22: 574-574. DOI: 10.1200/Jco.2004.22.90140.574  0.427
2003 Sparidans RW, Silvertand L, Dost F, Rothbarth J, Mulder GJ, Schellens JH, Beijnen JH. Simple high-performance liquid chromatographic assay for melphalan in perfusate, rat liver and tumour tissue. Biomedical Chromatography : Bmc. 17: 458-64. PMID 14598330 DOI: 10.1002/Bmc.273  0.434
2003 van Herwaarden AE, Jonker JW, Wagenaar E, Brinkhuis RF, Schellens JH, Beijnen JH, Schinkel AH. The breast cancer resistance protein (Bcrp1/Abcg2) restricts exposure to the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. Cancer Research. 63: 6447-52. PMID 14559835  0.347
2003 van Kesteren Ch, de Vooght MM, López-Lázaro L, Mathôt RA, Schellens JH, Jimeno JM, Beijnen JH. Yondelis (trabectedin, ET-743): the development of an anticancer agent of marine origin. Anti-Cancer Drugs. 14: 487-502. PMID 12960733 DOI: 10.1097/00001813-200308000-00001  0.558
2003 Bardelmeijer HA, Buckle T, Ouwehand M, Beijnen JH, Schellens JH, van Tellingen O. Cannulation of the jugular vein in mice: a method for serial withdrawal of blood samples. Laboratory Animals. 37: 181-7. PMID 12869279 DOI: 10.1258/002367703766453010  0.42
2003 Brandon EF, Raap CD, Meijerman I, Beijnen JH, Schellens JH. An update on in vitro test methods in human hepatic drug biotransformation research: pros and cons. Toxicology and Applied Pharmacology. 189: 233-46. PMID 12791308 DOI: 10.1016/S0041-008X(03)00128-5  0.399
2003 Van den Brande J, Schöffski P, Schellens JH, Roth AD, Duffaud F, Weigang-Köhler K, Reinke F, Wanders J, de Boer RF, Vermorken JB, Fumoleau P. EORTC Early Clinical Studies Group early phase II trial of S-1 in patients with advanced or metastatic colorectal cancer. British Journal of Cancer. 88: 648-53. PMID 12659110 DOI: 10.1038/Sj.Bjc.6600781  0.383
2003 Bardelmeijer HA, Oomen IA, Hillebrand MJ, Beijnen JH, Schellens JH, van Tellingen O. Metabolism of paclitaxel in mice. Anti-Cancer Drugs. 14: 203-9. PMID 12634614 DOI: 10.1097/00001813-200303000-00003  0.434
2003 Kruijtzer CM, Boot H, Beijnen JH, Lochs HL, Parnis FX, Planting AS, Pelgrims JM, Williams R, Mathôt RA, Rosing H, Schot ME, Van Tinteren H, Schellens JH. Weekly oral paclitaxel as first-line treatment in patients with advanced gastric cancer. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 14: 197-204. PMID 12562644 DOI: 10.1093/Annonc/Mdg078  0.637
2003 Schoemaker NE, Rosing H, Jansen S, Schellens JH, Beijnen JH. High-performance liquid chromatographic analysis of the anticancer drug irinotecan (CPT-11) and its active metabolite SN-38 in human plasma. Therapeutic Drug Monitoring. 25: 120-4. PMID 12548157 DOI: 10.1097/00007691-200302000-00020  0.483
2003 Crul M, van Waardenburg RC, Bocxe S, van Eijndhoven MA, Pluim D, Beijnen JH, Schellens JH. DNA repair mechanisms involved in gemcitabine cytotoxicity and in the interaction between gemcitabine and cisplatin. Biochemical Pharmacology. 65: 275-82. PMID 12504803 DOI: 10.1016/S0006-2952(02)01508-3  0.374
2003 Kruijtzer CM, Beijnen JH, Schellens JH. Improvement of oral drug treatment by temporary inhibition of drug transporters and/or cytochrome P450 in the gastrointestinal tract and liver: an overview. The Oncologist. 7: 516-30. PMID 12490739 DOI: 10.1634/Theoncologist.7-6-516  0.459
2003 Crul M, van Waardenburg RC, Beijnen JH, Schellens JH. DNA-based drug interactions of cisplatin. Cancer Treatment Reviews. 28: 291-303. PMID 12470980 DOI: 10.1016/S0305-7372(02)00093-2  0.391
2003 Van Kesteren C, Beijnen JH, Schellens JH. E7070: a novel synthetic sulfonamide targeting the cell cycle progression for the treatment of cancer. Anti-Cancer Drugs. 13: 989-97. PMID 12439332 DOI: 10.1097/00001813-200211000-00002  0.427
2003 Sparidans RW, Crul M, Schellens JH, Beijnen JH. Isocratic ion-exchange chromatographic assay for the nucleotide gemcitabine triphosphate in human white blood cells. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 780: 423-30. PMID 12401370 DOI: 10.1016/S1570-0232(02)00638-4  0.419
2003 van sen Bongard HJ, Pluim D, Rosing H, Nan-Offeringa L, Schot M, Ravic M, Schellens JH, Beijnen JH. An excretion balance and pharmacokinetic study of the novel anticancer agent E7070 in cancer patients. Anti-Cancer Drugs. 13: 807-14. PMID 12394264 DOI: 10.1097/00001813-200209000-00004  0.476
2003 Schellens J, Paz-Ares L, Trigo J, Pardo B, Ruiz-Casado A, Ciruelos E, Garcia M, Beijnen J, Izquierdo M. 549 Liver toxicity: a predictable and manageable toxicity for kahalalide F (KF) European Journal of Cancer Supplements. 1: S166. DOI: 10.1016/S1359-6349(03)90581-7  0.354
2002 Schoemaker NE, Mathôt RA, Schöffski P, Rosing H, Schellens JH, Beijnen JH. Development of an optimal pharmacokinetic sampling schedule for rubitecan administered orally in a daily times five schedule. Cancer Chemotherapy and Pharmacology. 50: 514-7. PMID 12451480 DOI: 10.1007/S00280-002-0516-5  0.611
2002 Crul M, Beerepoot LV, Stokvis E, Vermaat JS, Rosing H, Beijnen JH, Voest EE, Schellens JH. Clinical pharmacokinetics, pharmacodynamics and metabolism of the novel matrix metalloproteinase inhibitor ABT-518. Cancer Chemotherapy and Pharmacology. 50: 473-8. PMID 12451474 DOI: 10.1007/S00280-002-0515-6  0.385
2002 van Kesteren C, Mathôt RA, Raymond E, Armand JP, Fumoleau P, Punt C, Ravic M, Wanders J, Beijnen JH, Schellens JH. Development and validation of limited sampling strategies for prediction of the systemic exposure to the novel anticancer agent E7070 (N-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide). British Journal of Clinical Pharmacology. 54: 463-71. PMID 12445024 DOI: 10.1046/J.1365-2125.2002.01684.X  0.611
2002 Bardelmeijer HA, Ouwehand M, Buckle T, Huisman MT, Schellens JH, Beijnen JH, van Tellingen O. Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir. Cancer Research. 62: 6158-64. PMID 12414642  0.396
2002 Schoemaker NE, van Kesteren C, Rosing H, Jansen S, Swart M, Lieverst J, Fraier D, Breda M, Pellizzoni C, Spinelli R, Grazia Porro M, Beijnen JH, Schellens JH, ten Bokkel Huinink WW. A phase I and pharmacokinetic study of MAG-CPT, a water-soluble polymer conjugate of camptothecin. British Journal of Cancer. 87: 608-14. PMID 12237769 DOI: 10.1038/Sj.Bjc.6600516  0.494
2002 Schoemaker NE, Rosing H, Jansen S, Schöffski P, Rizzo J, Schellens JH, Beijnen JH. Determination of 9-nitrocamptothecin and its metabolite 9-aminocamptothecin in human plasma using high-performance liquid chromatography with ultraviolet and fluorescence detection. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 775: 231-7. PMID 12113990 DOI: 10.1016/S1570-0232(02)00294-5  0.481
2002 Herben VM, Schoemaker nE, Rosing H, van Zomeren DM, ten Bokkel Huinink WW, Dubbelman R, Hearn S, Schellens JH, Beijnen JH. Urinary and fecal excretion of topotecan in patients with malignant solid tumours. Cancer Chemotherapy and Pharmacology. 50: 59-64. PMID 12111113 DOI: 10.1007/S00280-002-0454-2  0.451
2002 van den Bongard HJ, Mathôt RA, van Tellingen O, Schellens JH, Beijnen JH. A population analysis of the pharmacokinetics of Cremophor EL using nonlinear mixed-effect modelling. Cancer Chemotherapy and Pharmacology. 50: 16-24. PMID 12111107 DOI: 10.1007/S00280-002-0459-X  0.607
Show low-probability matches.